

## CURRICULUM VITAE

November 6, 2017

### PERSONAL DATA:

Name: THOMAS A. PEARSON, M.D., M.P.H., Ph.D.  
Birthdate: October 21, 1950  
Birthplace: Berlin, Wisconsin  
Citizenship: U.S.A.  
HSPP #: 10960604

Signature:

 Date: 11/06/17

### ACADEMIC TRAINING:

1968 – 1971 University of Wisconsin, Madison, Wisconsin  
1971 – 1973 The Johns Hopkins University (B.A. Degree)  
1972 – 1976 The Johns Hopkins University, School of Medicine (M.D. Degree)  
1975 – 1976 The Johns Hopkins University, School of Hygiene and Public Health,  
Master of Public Health (Advisor – Dr. Leon Gordis)  
1976 – 1983 The Johns Hopkins University, School of Hygiene and Public Health,  
Ph.D. in Epidemiology (Thesis Advisor – Dr. Leon Gordis)  
Licensure: New York: 175541-1 NYS  
Florida: ME122156  
DEA AP2029252

### TRAINEESHIPS:

1976 – 1978: The Johns Hopkins University, School of Hygiene and Public Health,  
Resident in Preventive Medicine (Chief of Service – Dr. Edyth  
Schoenrich)  
1976 – 1979: The Johns Hopkins University, School of Medicine, Fellow in Pathology  
(Laboratory of Dr. R.H. Heptinstall)  
1979 – 1980: The Johns Hopkins University, School of Hygiene and Public Health,  
Chief Resident in Preventive Medicine  
1979 – 1980: Johns Hopkins Hospital, Intern in Medicine (Chief of Service – Dr.  
Victor McKusick)  
1980 – 1981: Johns Hopkins Hospital, Assistant Resident in Medicine (Chief of  
Service – Dr. Victor McKusick)  
1981 – 1983: The Johns Hopkins University, School of Medicine, Fellow in Internal  
Medicine and Cardiology (Chiefs of Service – Dr. Craig Smith and Dr.  
Myron Weisfeldt)

### BOARD QUALIFICATION:

March 1980 United States: Diplomate of the National Board of Medical Examiners  
September 1983 Diplomate, American Board of Internal Medicine  
November 1985 Diplomate, American Board of Preventive Medicine  
1988 Internal Medicine/Cardiovascular Diseases/Preventive Medicine  
Specialist, State of Maryland  
2005 Diplomate, American Board of Clinical Lipidology

PROFESSIONAL ORGANIZATIONS AND SOCIETIES:

1977 – Present	American Heart Association Council on Epidemiology
1977 – Present	American Heart Association Council on Atherosclerosis, Thrombosis, and Vascular Biology
1976 – Present	Alpha Omega Alpha, Past President of Johns Hopkins Chapter (1977)
1977 – 1990	Society for Epidemiologic Research
1983 – 2010	American Federation for Clinical Research
1983 – Present	Johns Hopkins Medical Surgical Society
1985 – 1997	American College of Epidemiology
1986 – Present	American College of Preventive Medicine, (Fellow, 1987)
1986 – Present	International Society and Federation of Cardiology Section on Epidemiology and Prevention
1986 – 2008	Association of Teachers of Preventive Medicine/Association of Prevention Teachers and Researchers
1986 – 1988	Mid Atlantic Lipid Society
1987 – Present	American College of Physicians, (Fellow, 1988)
1988 – 1997	The New York Academy of Sciences
1989 – 2003	American Association for the Advancement of Science
1990 – 1997	Otsego County Medical Society
1990 – Present	American Public Health Association
1990 – Present	American College of Cardiology, (Fellow, 1992)
1994 – 1997	National Rural Health Association
1994 – 1997	New York State Public Health Association
2000 – Present	American Heart Association Council on Nutrition, Metabolism, and Physical Activity
2003 – 2006	World Heart Federation, Board of Directors
2004 – Present	National Lipid Association (Fellow, 2009)
2004 - 2013	Monroe County Medical Society
2005 - 2007	The Leadership Council for Improving Cardiovascular Care (LCIC) Executive Committee
2006 - 2014	National Forum for Heart Disease and Stroke Prevention. Chair, Regional and Global Collaboration Implementation Group (2007-9). Chairman of Board of Directors (2010-2012) Immediate Past Chair (2012 – 2014)
2008 - 2010	Member, 2010 U.S. Dietary Guidelines Advisory Committee, U.S. Department of Agriculture, Department of Health and Human Services
2009 - Present	Member, Society for Clinical and Translational Research
2016 - Present	Member, Association for Academic Minority Physicians, National Research Mentoring Network

ACADEMIC APPOINTMENTS:

1983 – 1985	Assistant Professor of Medicine, Pathology and Epidemiology Johns Hopkins Schools of Medicine and Public Health
1985 – 1988	Associate Professor of Medicine and Epidemiology, Johns Hopkins Schools of Medicine and Public Health

1988 – 1997	Professor of Public Health (Epidemiology and Medicine), Columbia University College of Physicians and Surgeons – Division of Epidemiology, Columbia University School of Public Health and Department of Medicine
1988 – Present	Part-time Faculty, Department of Medicine, Johns Hopkins University, School of Medicine
1990 – 2013	Adjunct Professor, Division of Nutritional Sciences, Cornell University (Ithaca, NY)
1989 – 1997	Research Professor of Epidemiology, State University of New York at Albany, School of Public Health
1994 – 2013	Adjunct Professor, Department of Nutrition, College of Health and Human Development, The Pennsylvania State University
1995 – 1997	Jane Forbes Clark Chair in Health Research, Columbia University College of Physicians and Surgeons
1997 – 2007	Chair, Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry
1997-2013	Albert D. Kaiser Professor, Department of Community and Preventive Medicine, University of Rochester School of Medicine and Dentistry
1997 – 2013	Professor of Medicine, University of Rochester School of Medicine and Dentistry
2002 – 2013	Senior Associate Dean for Clinical Research, University of Rochester School of Medicine and Dentistry (Leave of Absence 7/07-6/08)
2004 – 2013	Director, Rochester Prevention Center/National Center for Deaf Health Research (Leave of Absence 7/07-6/08), University of Rochester School of Medicine
2006 – 2013	Director, Rochester Clinical and Translational Science Institute (Leave of Absence 7/07-6/08)
2007-2008	Visiting Scientist, National Human Genome Research Institute, National Institutes of Health
2013 – Present	Adjunct Professor of Medicine and of Public Health Sciences, University of Rochester School of Medicine and Dentistry
2013 – Present	Executive Vice President for Research and Education, University of Florida Health Science Center.
2013 – Present	Professor of Epidemiology and Medicine with tenure, Colleges of Public Health and Health Professions and College of Medicine, University of Florida

HOSPITAL APPOINTMENTS:

1983 – 1988	Attending Physician, Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD
1983 – 1988	Director, Johns Hopkins Preventive Cardiology Clinic, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD
1988 – 1997	Director, The Mary Imogene Bassett Research Institute, Cooperstown, New York
1988 – 1997	Attending Physician, Department of Medicine, The Mary Imogene Bassett Hospital, Cooperstown, New York
1993 – 1996	Director, Executive Health Program, Bassett Healthcare
1997 – 2013	Attending Physician, Department of Medicine, Strong Memorial Hospital, Rochester, New York
1997 – 2013	Director, Preventive Cardiology Clinic, Strong Memorial Hospital, Rochester, New York
2014 – present	Attending Physician, Department of Medicine, College of Medicine/UF Health
2015 – present	Co-Director, Lipid Disorders Clinic, UF Shands Hospital

UNIVERSITY/SCHOOL/DEPARTMENT COMMITTEES (Past 10 Years Only):

## University of Rochester (1997 – 2013)

## University:

2002-2013	Conflict of Interest Committee
2006-2007	Provost Search Committee
2008-2013	University Management Team
2008-2013	Deans' Entrepreneurship Committee
2010-2013	Sponsored University Research Group

## School of Medicine and Dentistry:

1997-2013	Medical Center Senior Advisory Committee
2002-2013	Medical Center Senior Advisory Committee Steering Committee
2002-2013	Associate Dean Executive Planning Team
2002-2013	Co-Chair, Clinical Research Review Process Improvement Team
2002-2013	Medical Scientist Training Program Executive Committee
2006-2013	Foundation and Industry Relations Committee
2006-2013	CRC Leadership Committee
2006-2013	CTSI Executive Committee, Chair (2009-Present)
2006-2013	CTSA Administrative Committee, Chair (2009-Present)
2008-2013	Mentor Development Core Committee
2008-2010	Strategic Plan Advisory Committee

2008-2013	URMC Community Advisory Council, Center for Community Health
2008-2011	Chair, CTSB Project Management Team
2009-2010	Departmental Chair Review Committee
2009-2013	Developmental Center for AIDS Research Internal Advisory Committee
2010-2011	Co-Chair, Scientific Advisory Committee

Department of Community and Preventive Medicine:

1999-2013	Graduate Program Committee
2004-2013	Chair, Residency Advisory Committee, Preventive Medicine Residency
2005-2013	Chair, PRC Executive Committee

University of Florida (2013 – present)

University:

2013 – present	Deans and Directors Committee
2014 – 2015	Best Practices in Graduate Education
2015 – present	Title IX Committee

UF Health:

2013 – present	Chair, Associate Deans for Research Committee
2013 – present	Chair, Associate Deans for Education Committee
2013 – present	Deans and Directors Committee
2013 – present	Department of Epidemiology Faculty Graduate Committee
2013 – 2016	Department of Medicine Research Advisory Committee
2014	Member, College of Dentistry Dean's Search Committee
2014 – 2015	Chair, UF Cancer Center Director Search Committee
2014 – 2015	Chair, Cancer Preeminence Initiative Coordinating Committee
2014 – 2015	Chair, Cancer Epidemiology and Control Subcommittee to Cancer Preeminence Initiative
2014 – present	Chair, Community Engagement Committee
2014 – present	Member, Clinical and Translational Science Governance Committee
2015 – 2016	Chair, McKnight Brain Institute Search Committee
2015 – present	Chair, Translational Workforce Development Directorate, UF CTSA Programs
2015 – present	Chair, Educational IT Steering Committee
2016 – 2017	Chair, HSC Library Director Search Committee
2017 – present	Member, Epidemiology Fund-raising Committee

HONORS:

1968	Phi Eta Sigma, University of Wisconsin
1970	R.I. Ingersoll Memorial Award for Excellence in Physics
1971	Phi Kappa Phi, University of Wisconsin
1971	Phi Beta Kappa and Speaker at Annual Banquet, University of Wisconsin
1973	B.A. with Honors, Johns Hopkins University
1975	Finalist, Medical Student Research Competitions, Johns Hopkins University School of Medicine
1976	Alpha Omega Alpha, Johns Hopkins University School of Medicine
1977	Passed with Distinction, Ph.D. Comprehensive Oral Examination, Johns Hopkins University School of Hygiene and Public Health

- 1978 Selected for Workshop on Epidemiologic Methods, sponsored by the Society for Epidemiologic Research and National Cancer Institute
- 1978 Student Research Prize Paper, 11<sup>th</sup> Annual Meeting of the Society for Epidemiologic Research
- 1980 Selected as one of “80 People to Watch in 1980” by Baltimore Magazine, 1/80
- 1983 Delta Omega, Public Health Honor Society, Johns Hopkins University School of Hygiene and Public Health, Alpha Chapter
- 1984 Maryland Heart Association Annual Appreciation Award
- 1986 Selected as one of “86 People to Watch in 1986” by Baltimore Magazine, 1/86
- 1986 Maryland Heart Association Annual Appreciation Award
- 1986 Elected Fellow, American Heart Association, Epidemiology Council
- 1987 Elected Fellow, American College of Preventive Medicine
- 1987 Presidential Award for Outstanding Volunteer Service, Maryland Affiliate of American Heart Association
- 1987 Sydney Cohen Award for Outstanding Contribution to the Understanding of Addiction, American Medical Association
- 1988 Elected Fellow, American College of Physicians
- 1988 Gold Certificate Honorable Mention, American Heart Association, Maryland Affiliate
- 1988 Governor’s Citation, State of Maryland, for Community Service
- 1988 Elected Fellow, American Heart Association, Council on High Blood Pressure
- 1989 American Men and Women of Science, 17<sup>th</sup> edition
- 1991 NIH Certificate of Appreciation
- 1992 AHA Certificate of Appreciation
- 1992 Fellow, American College of Cardiology
- 1992 Fellow, American College of Epidemiology
- 1996 Pfizer Visiting Professor in Cardiovascular Medicine, Morehouse College of Medicine, Atlanta, Georgia
- 1997 Joseph Stokes Award in Preventive Cardiology from the American Society of Preventive Cardiology
- 1999 Lewis Connor Memorial Lectureship, American Heart Association
- 2001 Fellow, American Heart Association
- 2002 Hederdokter (Honorary Doctor of Medicine), University of Umeå, Sweden
- 2004 American Association of Medical Colleges Award for Community Service to University of Rochester School of Medicine
- 2005 Association of Teachers of Preventive Medicine Outstanding Educational Program for 2005
- 2006 Fellow, Rochester Academy of Medicine
- 2007 The Naomi M. Kanof Award for Distinguished Achievement in Clinical Investigation, Society for Investigative Dermatology
- 2009 Fellow, National Lipid Association
- 2009 Johns Hopkins Society of Scholars
- 2010 Lifetime Mentoring Award, University of Rochester School of Medicine and Dentistry
- 2011 Rochester School for the Deaf Lyon Founder’s Award
- 2012 National Forum Service Award, National Forum for Heart Disease and Stroke Prevention
- 2012 Heart Healthy and Stroke Free Award, National Forum for Prevention of Heart Disease and Stroke
- 2013 Joseph Stokes III Memorial Lecturer, Boston University School of Medicine
- 2014 National Forum Leadership Award. National Forum for Heart Disease and Stroke Prevention

#### TEACHING EXPERIENCE:

- 1983 – 1988 Teaching Attending Physician, Nelson-Baker Medical Service, Johns Hopkins Hospital
- 1984 – 1988 Director: “Epidemiology and Prevention of Cardiovascular Disease” (Epidemiology 5), Johns Hopkins University
- 1983 – 1988 Cardiovascular Clinical Skills Instructor, Division of Cardiology
- 1983 – 1988 Annual Lecturer in Biochemistry, Pathophysiology, and Biochemistry Nutrition Courses (Year I, II Curriculum), The Johns Hopkins University School of Medicine
- 1983 – 1988 Rotating Instructor, Clinical Epidemiology, (Year II), The Johns Hopkins University School of Medicine
- 1983 – 1988 Advisor of Graduate Students, Department of Epidemiology, The Johns Hopkins University School of Medicine
- 1985 – 1986 Course Director: “Preventive Strategies in Medical Education.” Hangzhou, Peoples Republic of China
- 1984 – 1988 Co-Director: “Clinical Research Methods Course.” The Johns Hopkins University School of Medicine
- 1988 – 1997 Advisor of Graduate Students, Department of Epidemiology, Columbia University School of Public Health
- 1989 Course Director, “Clinical Research Methods Course,” The Mary Imogene Bassett Hospital
- 1989 – 1994 Annual Lecturer in Epidemiology Course (Year I), Columbia University College of Physicians and Surgeons
- 1990 Lecturer and Workshop Director, Epidemiology Course (Year I), Albany Medical College
- 1991 – 2001 Faculty Member, American Heart Association 10-Day Seminar on the Epidemiology and Prevention of Cardiovascular Disease, Lake Tahoe, California
- 1992 – 1997 Lecturer in Cardiovascular Epidemiology Course, Columbia University School of Public Health
- 1995 – 2000 Director, The Northeast Regional Lipid Training Center
- 1997 – 2003 Course Director, Introduction to Epidemiology, Graduate Program, Department of Community and Preventive Medicine
- 1997 – 1999 Course Director, Introduction to Community Medicine, Year I, University of Rochester School of Medicine
- 1997 Course Director, Introduction to Environmental Health, Graduate Program, Department of Community and Preventive Medicine, University of Rochester School of Medicine
- 1998 – 2013 Course Director, Practical Skills in Grant Writing, Graduate Program, Department of Community and Preventive Medicine, University of Rochester School of Medicine
- 1997 – 2006 Lecturer in Nutrition: Cell Structure and Function Course, Year I, University of Rochester Medical School
- 1998 – 1999 Co-Director: Implementing Coronary Risk Factor Modification: Why, How, and When. American College of Cardiology
- 1999 – 2007 Course Director, Mastering Medical Information (4 weeks), Year I MD Curriculum, University of Rochester School of Medicine.
- 1999 – 2007 Nutrition Theme Director, Double Helix Curriculum, University of Rochester School of Medicine

1998 – 2013	Lecturer in various courses in the MPH curriculum (PM421: Introduction to US Healthcare; PM418: Epidemiology and Prevention of Cardiovascular disease; Nursing 418: Principles of Prevention; PM 417: Molecular Epidemiology), University of Rochester Department of Community and Preventive Medicine
1999 – 2007	Lecturer in Molecules to Cells (17 hours). Integrated Systems (1 hour), Community Health Improvement Clerkship (4 hours) in MD curriculum, University of Rochester School of Medicine
1999-2013	Course Director: Introduction to Clinical Research (4 hours) Summer Lecture Series
2008-2011	Lecturer, Academic Research Track Series, MD Curriculum
2008-2010	Lecturer and PBL Tutor, Mastering Medical Informatics (1-hour lecture), Year I MD Curriculum, University of Rochester School of Medicine
2009	Lecturer, Molecules to Cells (1-hour case presentation), University of Rochester School of Medicine
2003 – 2007, 2010	Lecturer, Process of Discovery Course, Year IV MD Curriculum, University of Rochester School of Medicine
2003 – 2013	Coordinator, Empire Clinical Research Investigator Program (ECRIP)
2003 – 2009	Director, Clinical Translational Research Seminar Series (Leave of Absence, 2007-8)
2006 – 2008	Director, Education and Training Key Function, Rochester Clinical and Translational Science Award, University of Rochester School of Medicine
2008	Co-Director of NHGRI-sponsored course: “Genetics for Epidemiologists,” Northwestern University
2008	Co-Director of NHGRI-sponsored course: “Epidemiology for Investigators Performing Genomic Studies,” NIH
2008 – 2010	Director, National CTSA Educational Resource Program, National CTSA Consortium
2010 – 2011	Co-Convener, Personalized Medicine, Process of Discovery Course Year IV MD Curriculum, University of Rochester School of Medicine
2010 - 2011	Chair, CTSA Strategic Goal Committee #2 Training and Career Development, CTSA National Consortium. Team Leader – Core Curriculum Committee
2014 – present	Workshops and “Boot Camp” Series on grant writing and administration of training grants, career development needs, conversation of K to R grants, etc.

#### GRADUATE STUDENTS AND FELLOWS SUPERVISED:

1982 – 1985	Linda P. Fried, M.D., M.P.H.	Fellow
1983 – 1986	Robin Miller, M.D., M.H.S.	Fellow
1984 – 1987	Teri Manolio, M.D., M.H.S.	Fellow
1984 – 1988	Carol Derby, Ph.D.	Graduate Student
1984 – 1985	Andrea P. Lacroix, Ph.D.	Fellow
1985 – 1987	Marilyn Menkes, Ph.D.	Fellow
1987	Prithiva Chanmugan, Ph.D.	Fellow
1987 – 1990	Shen-Qiang Yu, M.D.	Fellow
1986 – 1988	Stephen Coughlin, Ph.D.	Graduate Student
1985 – 1988	David Herrington, M.D., M.H.S.	Fellow
1985 – 1988	Jorge Trejo-Gutierrez, M.D., M.H.S.	Fellow
1986 – 1988	Roy Fried, M.D., M.H.S.	Fellow
1987 – 1988	William Sigmund, M.D., M.H.S.	Fellow
1988 – 1994	Stephen Bowlin, D.O., M.P.H.	Fellow/Grad. Student
1988 – 1990	Anne Nafziger, M.D.	Fellow
1989 – 1990	Beth Benson, M.D.	Fellow



1989 – 1990	Charles B. Eaton, M.D.	Fellow
1989 – 1992	Sarah Olson	Graduate Student
1990 – 1991	Barbara A. Dennison, M.D.	Fellow
1990 – 1991	Richard Carroll, M.D.	Fellow
1990 – 1995	Lori Mosca, M.D., Ph.D.	Fellow/Grad. Student
1992 – 1995	Matthews K. Hurley, M.D.	Minority Investigator
1983 – 1988	Paul Terry	Graduate Student
1993 – 1994	Fernando Lapetina, M.D.	Fellow
1994 – 1995	Jose Mathew, M.D.	Fellow
1994 – 1995	James LaCava, M.D.	Fellow
1995 – 2002	Barbara Rothenberg, Ph.D.	Graduate Student
1995 – 2003	Christi Davis	Graduate Student
1996 – 1997	Merle Myerson, M.D.	Fellow
1997 – 2002	Ronald Gottlieb, M.D.	Part time MPH Student
1997 – 2000	Mark Hostetler, M.D.	MPH Student
1998 – 2005	I. Diana Fernandez, M.D., Ph.D.	Fellow, K08 Awardee
1999 – 2001	Patricia Stewart, R.D., Ph.D.	Fellow
1999 – 2005	Jeffrey Bazarian, M.D.	MPH Student, K23 Awardee
1999 – 2002,		
2004 - 2006	Lanette Brown, MD	MD/MPH Student, Fellow
2000 – 2010	Jacob Adams, M.D.	Fellow, K23 Awardee
2001 – 2003	Doru Chirieac, M.D.	Fellow
2001 – 2002	Nilda Hernandez, Ph.D.	Fellow
2001 – 2004	Mark Fox, M.D., Ph.D.	Fellow, K23 Awardee
2001 – 2004	Yazid Fadl, M.D.	Fellow
2001 – 2003	Charlene Pope, Ph.D., M.P.H., C.N.M.	Fellow
2000 – 2002	Lowell Goldsmith, M.D.	MPH Student
2001 – 2004	Arvan Robinson, M.D.	MPH Student
2002 – 2004	Laurent Glance, M.D.	K23 Awardee
2002 – 2004	Carolyn Tabak, M.D.	Fellow
2003 – 2005	Deborah Levy, MD	Fellow
2003 – 2009	Matthew Wilson, MD	Fellow
2004 – 2013	Robert Block, MD	Fellow, KL2 Awardee
2004 – 2013	Manish Shah, MD	K23 Awardee
2005 – 2006	Abiola Dela-Michael, MD	MD/MPH Student
2005 – 2010	Yanfang Ren, DDS, PhD	K23 Awardee
2005 – 2006	Douglas Ball, MD	Preventive Medicine Resident
2006 – 2013	Steven Barnett, MD, MPH	K23, K18 Awardee
2008 – 2013	Michael McKee, MD	Fellow, K01 Awardee
2008 – 2013	Scott Smith, MD, MPH	Fellow, K01 Awardee
2009 - 2011	Christopher Ombrello, MD	Fellow
2010 – 2012	Thomas Fugate	MD Student
2010 – 2017	Daniela Geba, MD	Graduate Student
2010 – 2013	Militza Moreno, MD	Fellow
2011 – 2012	Ana Espinosa, MD	Fellow
2012 – 2013	Tamala David, PhD, RN	Postdoctoral Fellow
2015 – 2017	Hannah Crooke	Graduate Student
2015 – present	Faheem Guirgis, MD	KL2/K23 Awardee
2016 – present	David Cheng, PhD	K07 Awardee

2016 – present

Lusi Yaghiyan, PhD

Epidemiology Jr. Faculty

OTHER PROFESSIONAL ACTIVITIES:Centers for Disease Control and Prevention

1999 – 2003	Chair, Cardiovascular Health Practitioners Institute
2001 – 2004	Member, Steering Committee, National CVD Action Plan
2001 – 2004	Chair, Working Group B (Infrastructure and Training), National CVD Action Plan
2004 – 2013	Steering Committee, National Forum to Prevent Heart Disease and Stroke
2004 – 2013	Member, PRC Directors Group
2004 – 2005	Speaker, Conference on Polypill
2005 – 2009	Chair, Regional and Global Partnerships Implementation Group, National Action Plan for Cardiovascular Health
2005 – 2010	Director, Coordinating Center, National Cardiovascular Health Intervention Network
2011	Member, Search Committee for Director of Division of Heart Disease and Stroke Prevention

National Forum for Heart Disease and Stroke Prevention

2008 - 2009	Chair Elect
2010 – 2012	Chair, Board of Directors
2010	Chair, 8 <sup>th</sup> National Forum Conference Committee
2011	Chair, 9 <sup>th</sup> National Forum Conference Committee
2011 – 2013	Steering Committee, Policy Depot Project
2012 – 2014	Immediate Past Chair; Member, Board of Directors

National Academy of Sciences/Institute of Medicine:

1997	Committee on Research, Development, and Institutional Strengthening for Control of Cardiovascular Diseases in Developing Countries
2000 – 2006	Board on Population and Public Health Practice
2003	Committee for the Workshop on the Medicolegal Death Investigation System.

National Board of Medical Examiners:

1993 – 1995	Preventive Medicine and Public Health Test Committee
1993 – 1995	United States Medical Licensing Examination Test Material Development Committee for Preventive Medicine and Public Health

National Institutes of Health:

1984 – 2000	Member, Monitoring Board, CARDIA Project, National Heart, Lung, and Blood Institute. Chair (1987 – 2000).
1985	Study Section Member, “Childhood Nutrition, Physical Activity and Cardiovascular Health,” (NHLBI), National Institutes of Health, Bethesda, Maryland
1985	Workshop on Atherogenesis and Aging, National Institute of Aging, Graylyn Conference Center, Wake Forest University, Winston-Salem, North Carolina
1985	Study Section Member, NHLBI Physician Scientist Award, National Heart, Lung, and Blood Institute, Bethesda, Maryland

- 1986 Study Section Member, "Preventive Cardiology Academic Awards" (NHLBI) National Institutes of Health, Bethesda, Maryland
- 1986 Study Section Member, "Prevention of Bypass Graft Atherosclerosis Clinical Center." (NHLBI) National Institutes of Health, Bethesda, MD
- 1986 Discussant: NHLBI Workshop on the Decline in CHD mortality
- 1987 – 2000 Chairman, CARDIA Review Board, NHLBI
- 1987 – 1991 Member, Clinical Applications and Prevention Advisory Committee of the National Institutes of Health
- 1988 Consultant, Concept Development Meeting for National Heart, Lung, and Blood Institutes, News Media Campaigns
- 1988 Ad Hoc Site Visitor, Clinical Trials Branch, NHLBI
- 1988 Chairman of Session: Trends and Determinants of CHD Mortality. II. International Comparisons. NIH, Bethesda
- 1988 Organizing Committee, NIH Conference on Occupational Stress
- 1988 Speaker at National Heart, Lung, and Blood Institute meeting of State Health Officers, Western U.S., Boulder, Colorado
- 1988 Reviewer by mail, Surgery and Bioengineering Study Section, National Institutes of Health
- 1989 Consultant, National Heart, Lung, and Blood Institute, Contracts, Clinical Trials, and Training Review Section
- 1989 Chair, Clinical Applications and Prevention Advisory Committee, National Institutes of Health
- 1990 Planning Committee and Writing Task Force, Workshop on Cholesterol in Women and the Elderly, National Heart, Lung, and Blood Institute, Bethesda
- 1990 Federal Government Consultant for the Evaluation of Demonstration and Education Research Grants, Washington, DC
- 1990 Chair, Overseas Studies, National Heart, Lung, and Blood Institute Conference on Low Blood Cholesterol Levels, Washington, DC
- 1991 Invited speaker, Cardiology Advisory Committee, National Heart, Lung, and Blood Institute, Washington, DC
- 1991 Organizing Committee and Discussant, Workshop on the Prevalence and Etiology of Idiopathic Dilated Cardiomyopathy
- 1991 – 1999 Chairman, Data Monitoring Board, VA Coop. Study, 363: The VA HDL Intervention Trial, Veterans' Administration
- 1992 – 1993 Member, Steering Committee, NASBP Breast Cancer Prevention Trial
- 1992 Chair, Diagnosis and Case-Finding Session, NHLBI Workshop "Identification and Management of Heterozygous Familial Hypercholesterolemia."
- 1992 – 1993 Member, NHLBI Task Force on Research in Epidemiology and Prevention of Cardiovascular Disease
- 1993 – 1998 Member of Steering Committee, Chair of Steering Committee (1996 – present), and Chair of Laboratory Subcommittee (1993 – 1996), Dietary Effects on Lipids and Thrombogenic Activity (DELTA) Study
- 1994 Member, Cardiac Diseases Advisory Committee, The National Heart, Lung, and Blood Institute
- 1994 Member, Working Group, Impact of Cholesterol Guidelines in Secondary Prevention, National Heart, Lung, and Blood Institute

- 1994 Member, Ad Hoc Review Panel on Implementation of Physical Activity Into Preventive Care
- 1994 Member, Special Review Committee, National Institute on Alcohol Abuse and Alcoholism
- 1995 Member, Special Emphasis Panel, Division of Heart and Vascular Disease
- 1995 Member, Research Training Review Committee, National Heart, Lung, and Blood Institute
- 1995 Invited Speaker, U.S.-Italy Joint Symposium on “Clinical Trials: Past and Future,” Rome, Italy
- 1995 Invited Speaker, “Socioeconomic Status and Cardiovascular Health and Disease.” The National Heart, Lung, and Blood Institute, Bethesda, MD.
- 1996 – 1999 Member and Acting Chair, Special Emphasis Panel on Training, Division of Research Grants
- 1996 Member, National Heart, Lung, and Blood Institute Special Emphasis Panel on “New Opportunities for Studies of CVD Risk Factor Development and Early Vascular Disease in Children and Adolescents” Washington, D.C., September 11, 1996.
- 1996 Scientific Chairperson, National Heart, Lung, and Blood Institute conference “Cardiopulmonary Risk Factor Reduction Through Communities or Community Institutions: Implications for Preventive Strategies...” Washington, DC, September 25-26, 1996.
- 1996 Faculty, “Genetics of Complex Cardiac and Pulmonary Diseases.” Bar Harbor, Maine, October 7, 1996.
- 1998 – 2000 Member, Working Group on Cardiovascular Epidemiology and Biostatistics
- 1998 – 1999 Member, SPARK Group, National Heart, Lung, and Blood Institute
- 1999 Chair: National Conference on CVD Prevention: Meeting the Nation’s Year 2010 Objectives in Cardiovascular Health.
- 1999 Member, Steering Committee, COURAGE Study, Veterans Administration
- 2000 Consultant, Jackson Heart study, NHLBI.
- 2000 Chair, Special Emphasis Panel for Review of Nutrition Academic Award Applications
- 1998 – 2004 Chair, Steering Committee. Nutrition Academic Award Program
- 2001 Chair, Special Emphasis Panel for Review of Multicenter Projects
- 2001 Reviewer, Adult Treatment Panel III Report, National Cholesterol Education Program
- 2004 Member, Special Emphasis Panel for K01/K08 Awards, NHLBI
- 2004 – 2013 Member, External Advisory Board, Jackson Heart Study, NHLBI
- 2004 Site Visitor, University of Maryland Program Review, NHLBI
- 2005 Chair, Special Emphasis Panel for Career Development Awards, NHLBI
- 2005 – 2006 Chair, Protocol Review Committee, CLEVER Trial, NHLBI.
- 2006 Member, Coronary Artery Disease and Atherosclerosis Working Group, NHLBI Strategic Plan
- 2006 Speaker, Workshop on C-reactive Protein: Basic and Clinical Research Needs, NHLBI, July 10-11, 2006
- 2006 Consultant, Special Emphasis Panel Review – NIH National Research Service Award Institutional Research Training Grant (T32), November 27, 2006.

2006 - 2012	Chair, Data Safety and Monitoring Board, CLEVER Trial, NHLBI
2008	Member, Search Committee, Deputy Director, NCRR
2008 – 2016	Co-Chair, Implementation Working Group, Guideline Development Program, NHLBI
2008	Chair, Special Emphasis Panel Review – Using WHI Biological Specimens Effectively, NHLBI
2008	Member, Workshop on Development of Research Plan for the Women’s Health Initiative, NHLBI
2008 – 2009	Chair, Cardiovascular Working Group, PhenX Project, NHGRI
2009 – 2011	Chair, Strategic Goal Committee #2 (Education, Training, and Career Development) National Clinical and Translational Science Program, NCRR
2009 – 2013	Member, CTSA Consortium Steering Committee, National CTSA Consortium, NCATS
2010	Reviewer, Loan Repayment Program, NHLBI
2010	Heart Truth Professional Panel, Office of Women’s Health, NIH
2011-2013	Member, CTSA Consortium Executive Committee, National CTSA Consortium
2011	Chair, Review Panel, NHLBI Contract (Telephone Review)
2011	Plenary Presenter, 2 <sup>nd</sup> Sino-American Symposium of Translational Research, Shanghai, China June 25, 2011
2011 – 2013	Liaison to NIDCD, CTSA National Consortium, NCATS
2014	Reviewer, NHLBI Institutional Training Grant Study Section
2015, 2016	Presenter, NIMHD Workshop on the Science of Prevention and Health Promotion to Address Health Disparities. Bethesda, MD
2016	Member: Pulmonary, Cardiovascular and Musculoskeletal Epidemiology Study Section, NIH ZRG1 PSE-HO2, March 15, 2016
2016 – present	Association for Academic Minority Physicians, Inc., Member, National Research Mentoring Network

American College of Cardiology:

1993 – 1995	AHA Representative and Member, Committee on Prevention of Cardiovascular Disease
1993 – 1994	Working Group Co-Chair, Bethesda Conference on Future Personnel Needs in Cardiovascular Health Care
1994 – 1996	Co-Chair, Bethesda Conference #27 in Preventive Cardiology
1995	Co-Director, 12 <sup>th</sup> Annual Santa Fe Colloquium on Cardiovascular Therapy
1996	Ad Hoc Advisory Committee on Risk Factor Management Practices Survey
1997 – 1998	Member, Annual Scientific Session Program Committee
1998 – 1999	Co-Director, Risk Factor Modification: Who, When, and Why? Heart House Course
1998 – 1999	Member, Committee on Demographic Trends
2008-2009	Member, Performance Measures Writing Group: Primary Prevention of Coronary Heart Disease

American Heart Association:

1983 – 1986	Vice Chairman, Research Committee, Maryland Heart Association (AHA Affiliate)
1985 – 1988	Member, Board of Directors and Executive Committee, American Heart Association, Maryland Affiliate
1985 – 1988	Maryland Representative to AHA Middle Atlantic Regional Research Committee
1986 – 1988	Vice President and Chairman of the Research Committee, American Heart Association, Maryland Affiliate

1987 Ad Hoc Member, National Research Committee, American Heart Association

1987 Abstract Reviewer, American Heart Association

1987 – 1988 Chairman of the American Heart Association Middle Atlantic Regional Research Committee

1987 – 1992 Member, National Research Committee of the American Heart Association, (Co-Chairman of Review Section C)

1987 – 1991 Co-Chairman and Chairman, Lipoprotein, Lipid Metabolism and Epidemiology Research Study Committee of the American Heart Association

1987 – 1992 Member, American Heart Association Epidemiology Council

1988 – 1992 National Program Committee. American Heart Association and AHA Epidemiology Council

1989 – 1994 Chairman, Working Group on Preventive Cardiology Monograph for Medical Students

1989 – 1991 Chairman, Subcommittee to Increase Involvement of Women and Minorities in AHA

1990 Member, Planning Committee, American Heart Association Prevention Conference III

1990 Keynote Speaker, American Heart Association, Wood County Division Meeting, Marshfield, WI

1991 Invited Speaker, 18<sup>th</sup> Annual Science Writers Forum, Savannah, GA

1991 - present Abstract Reviewer

1991 Inaugural Chairman, Behavioral Science, Epidemiology and Prevention Study Committee

1991 – 2002 Faculty Member, Annual Ten-Day Seminar on the Epidemiology and Prevention of Cardiovascular Diseases, Tahoe City, CA

1992 – 1994 Co-Chairman, AHA Writing Group, Medical/Scientific Statement “Optimal Risk Factor Evaluation and Follow-up for Patients Undergoing Surgical and Non-Surgical Coronary Revascularization.”

1992 – 1995 AHA Representative to the American College of Cardiology Prevention of Cardiovascular Disease Committee

1993 Advisory Group for AHA Health Care Site Product Development

1993 Leader, Lipids Section, AHA Prevention III Conference, Monterey, CA

1993 – 1998 Member, Nutrition Committee

1993 – 1995 Member, Task Force on Cholesterol

1993 – 1996 Member, Research Program and Evaluation Committee

1994 – 1996 Vice Chairman, Council on Epidemiology and Prevention

1994 – 2001 Member, Executive Committee of Council on Epidemiology and Prevention

1995 – 1996 Member, Task Force on Risk Reduction

1995 – 1996 Member, Task Force on Preventive Cardiology

1995 – 1997 Chairman, Task Force on Council Member Participation in Affiliates/Divisions

1996 – 1998 Chairman, Council on Epidemiology and Prevention

1999 – 2001 Member, Scientific Advisory and Coordinating Committee

1996 – 1998 Prevention Coordinating Committee

1998 – 1999 Vice-Chair, Population Science Committee

1999 – 2001 Chair, Population Science Committee

1999 – 2001	Member, Population Wellness Committee
2000 – 2002	Chair, Primary Prevention Guidelines Writing Group
2001 – 2002	Co-Chair, Workshops on Inflammatory Markers and Cardiovascular Disease
2003 – 2006	Member, Secondary Prevention Guidelines Writing Group
2008 – 2010	Member, Guidelines for Primary Prevention for Stroke Writing Group
2003 – 2013	Chair, Guidelines for Prevention of Heart Disease and Stroke at the Community Level Writing Group

Association of American Medical Colleges:

2005	Speaker, Conference of the MD-MPH Education Community: Training Future Physicians to Synthesize Public Health and Medicine. June 27-28, 2005
2006	Principal Investigator of Rochester site: Regional Medicine-Public Health Education Centers
2006	Site Visitor, AAMC – CDC Interactions, June 26, 2006
2006	Participant, AAMC Committee on Comprehensive Training Track for Clinical and Translational Physician-Scientists, June 30, 2006
2006	Co-Chair, Undergraduate Committee, AAMC Committee on Comprehensive Training Track for Clinical and Translational Physician-Scientists
2007 – 2009	Member, Independence before 35 Working Group
2010 – 2013	Member, GRAND Steering Committee

United States Department of Agriculture/Department of Health and Human Services

2008 – 2010	Member, 2010 U.S. Dietary Guidelines Advisory Committee. Chair, Fatty Acids Working Group. Member, Alcohol, and Water and Electrolyte Working Groups
-------------	--

Other Universities (Current Only):

2005 – Present	Consultant, Clinical Research Training Program, Morehouse School of Medicine
2006 – 2013	Co-Director, Upstate New York Translational Research Network (UNYTE)
2006 – 2012	Member, External Advisory Committee, Stroke Research Center, Morehouse School of Medicine
2008 – 2012	Lecturer; Lipid Training Program, Johns Hopkins University School of Medicine
2008 – Present	External Advisory Committee, Georgia CTSA Program
2009 – 2013	External Advisory Committee, University of Florida CTSA Program
2010 – 2012	External Advisory Committee, Mayo Clinic CTSA Program
2010, 2012	Chair, Mock Site Visit, University at Buffalo CTSA Program
2010	Visiting Professor, Zhejiang University School of Medicine, Hangzhou, PRC 6/12-14/10
2011	Advisor, Mock Site Visit, University of Michigan CTSA Program
2011 – Present	Member, External Advisory Committee, R-Center Program, Morehouse School of Medicine
2012, 2014	External Advisory Board, Unity of Alabama-Birmingham CTSA Program
2012	Consultant, CTSA Renewal Team, Scripps Clinic CTSA Program
2016 - Present	External Advisory Committee, Clinical and Translational Science Program, Medical University of South Carolina
2016	Visiting Professor and Lecturer, Florida State University College of Medicine

International Organizations:

1985 – 1986	Director, course entitled “Preventive Strategies in Medical Education,” funded by the World Bank, Hangzhou, People’s Republic of China, March 1986
1990	Invited Speaker, World Bank/INCLLEN Program on Health Promotion in the Developing World, Puebla, Mexico
1990	Invited Speaker, International Symposium on Health, Environment, and Social Change, Taipei, R.O.C.
1993	Invited Speaker, II KTL Symposium on Chronic Disease Prevention, Helsinki, Finland
1993 – 2001	Member, Implementation Committee for the Victoria Declaration
1994	Invited Speaker, National Academy of Sciences Symposium: Disease Trends in the Newly-Independent States
1995 – 1997	Organizing Committee, 4 <sup>th</sup> International Conference on Preventive Cardiology, Chair, International Liaison Committee
1996	Lecturer, World Bank Health Resources Sector Professional Development Week, Leesburg, VA, Jan. 11, 1996
1996	Antwerp University Program, Antwerp, Belgium, September 13 – 15, 1996
1996	Invited Speaker, Nobel Prize Jubilee for 1985 Nobel Prize in Science and Medicine. Swedish Society of Cardiology, Stockholm, Sweden
1996	Consultant, Swedish Office of Technology Assessment, Stockholm, Sweden
1997	Faculty, Heart Care Network, European Study of Cardiology, Nice, France
1997 – 1998	Organizing Committee, International Heart Health Conference, Singapore
1997 – 1999	Chair, Singapore Declaration Committee
1998 – 2001	Organizing Committee, Fifth International Conference on Preventive Cardiology, Osaka, Japan, 2001.
1997 – 1999	Co-Chair, Forum for Global CVD Prevention, Chair, Education Subcommittee, World Heart Federation
1999 – 2003	Executive Committee, Forum for Global CVD Prevention, World Heart Federation
2000 – 2006	Chair, Education Task Force for Global CVD Prevention, World Heart Federation
2003 – 2004	Scientific Chair, International Heart Health Conference, Milan, Italy
2003 – Present	Founding Member, International Heart Health Network
2003 – 2005	Member, Board of Directors, World Heart Federation
2004	Faculty, Course on Heart Disease Prevention, Novgorod Medical Alliance. Novgorod, Russian Federation
2004 – 2006	Co-Principal Investigator and Scientific Director, Grenada Heart Project, World Heart Federation
2005	Reviewer, World Health Organization Report: “Preventing Chronic Disease: A Vital Investment.”
2009	Presenter and Consultant, St. Michaels Hospital, “Cardiovascular Disease Policies in India”, Toronto, Canada
2014 - 2015	Consultant/External Reviewer of Science for Life Laboratory, Swedish National Research Council, Stockholm, Sweden

Community and Private Sector Organizations (Current Only)



2002 – Present	Board of Directors, Security Mutual Life Insurance Company of New York (Compensation, Audit, and Marketing Committees)
2006 – Present	Coordinating Board, ARRIVE Study, A.G. Bayer and Co.
2011 – Present	Advisory Committee, Finger Lakes Cultural and National History Museum
2011 – 2013	Chair, Expert Committee, Health Engagement and Action for Rochester's Transformation (HEART)

#### MANUSCRIPT REVIEWER:

American Journal of Cardiology  
 American Journal of Clinical Nutrition  
 American Journal of Epidemiology  
 American Journal of Medicine  
 American Journal of Pathology  
 American Journal of Preventive Medicine  
 Annals of Internal Medicine  
 ATVB  
 British Medical Journal  
 Circulation  
 CVD Prevention  
 Epidemiology Reviews  
 Evidence-Based Cardiovascular Medicine  
 Journal of the American Medical Association  
 Journal of Cardiovascular Risk  
 Journal of Clinical Investigation  
 Journal of General Internal Medicine  
 Medicine  
 New England Journal of Medicine  
 Preventive Medicine  
 Scandinavian Journal of Public Health

#### LECTURESHIPS:

1. William J. Noble Distinguished Lectureship, St. Francis Hospital, Roslyn, New York, September 16, 1992.
2. DeStevens Lectureship. Northwestern University, Chicago, Illinois, April 2, 1993.
3. Keynote Lecture – Cardiology at the Limits, University College of London. Presented at University of Capetown, Capetown, South Africa, April 17, 1998.
4. Keynote Lecture – 6<sup>th</sup> International Conference on Noninvasive Cardiology, Jerusalem, Israel, December 20, 1998.
5. Lewis Connor Memorial Lecture, American Heart Association Scientific Sessions, Atlanta, Georgia, November, 1999.
6. Keynote Lecture: L.J. Filer, Jr. Third International Conference on Atherosclerosis in the Young, March 13, 2000.
7. The Bernard and Helen Perlman Lecture, “How Aggressive Should Lipid Therapy Be?”, 72<sup>nd</sup> Annual

Scientific Session, The New York Cardiological Society, Inc., September 23, 2000.

8. The Louis S. Peery and Janet B. Peery Lecture in General Internal Medicine: “The Secondary Prevention of Coronary Heart Disease: Where Do We Go From Here?” Medicine Grand Rounds, University of Utah School of Medicine, Salt Lake City, Utah, July 27, 2000.
9. Inaugural Simeon Margolis Lectureship in Preventive Cardiology, Johns Hopkins University School of Medicine, September 25, 2000: “Evidence-based Management of Patients with Coronary Disease in 2000.”
10. The Bernard Tabatznick, MD Lectureship: “Developing Evidence-Based Guidelines: Inflammatory Markers and Cardiovascular Disease.” Medical Grand Rounds, Sinai Hospital, Baltimore, Maryland, May 15, 2003.
11. 2<sup>nd</sup> Annual Albert Oberman Lecture: “Is There a Fifth Phase in the Epidemiologic Transition?” University of Alabama at Birmingham, November 18, 2004.
12. The Santa Fe Lecture, “Cardiovascular Disease Prevention in 2005: How are we doing? Could we do better?” Santa Fe Conference on Cardiovascular Disease (ACC), October 6, 2005.
13. L.L. Braun Lecture, “The Worldwide Epidemic of Coronary Disease: Why the Apathy?” Advocate Illinois Masonic Medical Center, January 31, 2007.
14. Naomi M. Kanof Lecture, Society for Investigative Dermatology, May 10, 2007.
15. The Lynn Smaha Memorial Leadership: “Cardiovascular Genomics” Guthrie Clinic Cardiovascular Disease Symposium, Corning, New York, October 11, 2008
16. Office of Research Distinguished Lecturer: “How to Interpret a Genome-wide Association Study” University of Mississippi, July 24, 2008
17. Keynote Lecture and Visiting Professor: Guideline Implementation: The Last Step in Research Translation. Annual Meeting, Clinical and Translational Science Award Program, University of California-Davis. July 29-30, 2009
18. Commencement Address: “T-Shaped People”, Master’s Degree Ceremony, University of Rochester School of Medicine and Dentistry, May 14, 2011.
19. Joseph Stokes III, MD Memorial Lectureship: “Let’s Get Serious about Preventing Heart Disease! The Science of Implementation of Preventive Cardiology Guidelines.” Boston University, March 1, 2013
20. Keynote Lecturer: “The Culture of Health: Can the Social Determinants of Heart Disease and Stroke Be Managed?” American Heart Association Epidemiology/Lifestyle 2016 Scientific Session. Phoenix, Arizona, March 2, 2016.
21. Distinguished Lecture: “Precision Public Health in the Prevention of Heart Disease and Stroke.” University of Alabama – Birmingham Comprehensive Cardiovascular Center, October 5, 2017.

22. Spotlight Presentation: “Finding and Fostering the Early Stage Investigator.” Research Center in Minority Institutions Translational Science 2017, Washington, DC, November 1, 2017.

RESEARCH GRANTS OBTAINED AS PRINCIPAL INVESTIGATOR:

1. Preventive Cardiology Academic Award. National Heart, Lung, and Blood Institute. Principal Investigator 1983-88. \$399,606.
2. Effects of Verapamil on Blood Lipids. G.D. Searle Pharmaceutical Co. Principal Investigator 1984-85. \$69,967.
3. Precursors of Premature Disease and Death. National Institute on Aging. Principal Investigator 1984-86. \$336,920.
4. Psychobiological Precursors of Cancer. National Cancer Institute. Principal Investigator 1984-87. \$395,757.
5. Core Functions of the Precursors Study. Johns Hopkins University School of Medicine. Principal Investigator 1984-88. \$31,966 (each year).
6. Johns Hopkins Physicians Lipid Education Program. Parke-Davis/Warner-Lambert Co. Principal Investigator 1985-86. \$40,654.
7. Cardiovascular Reactivity as a Precursor to Cardiovascular Disease. John D. and Catherine T. MacArthur Foundation. Principal Investigator 1986-87. \$27,110.
8. Study of the Effect of Coffee Consumption on Blood Lipids. National Coffee Association. Principal Investigator 1986-87. \$175,936.
9. Randomized Trial of Gemfibrozil in Hyperapobetalipoproteinemia. Parke-Davis/Warner-Lambert Co. Principal Investigator 1986-88. \$100,786.
10. Genesis of Atherosclerotic Lesions. National Heart, Lung, and Blood Institute. Principal Investigator 1986-1991. \$696,877.
11. Research Training in Preventive Cardiology. National Heart, Lung, and Blood Institute. Principal Investigator 1986-1991. \$753,145.
12. Youthful Precursors of Mortality. Phillip Morris Inc. Principal Investigator 1987. \$199,136.
13. Johns Hopkins Physicians Lipid Education Program. Health Scan, Inc. Principal Investigator 1987-88. \$17,500.
14. Youthful Predictors of Alcoholism. J.M. Foundation. Principal Investigator 1988. \$15,000.
15. Precursors of Premature Disease and Death. National Institute on Aging. 1988 – 1993. Principal Investigator 1988. \$726,048.
16. Private Census of Otsego County, New York. S.C. Clark Foundation 1988-89. \$150,000.

17. Development of Computer Assisted Instruction Module. Subcontract from JWK. International and National Heart, Lung, and Blood Institute. 1988-1990. \$36,000.
18. Cardiovascular Disease in Black and White Physicians. National Heart, Lung, and Blood Institute. Principal Investigator 1988-1993. \$1,960,860.
19. Community Cardiovascular Intervention Program. New York State Department of Health 1988-1997. \$209,425 per year.
20. Clinical Trial of Simvastatin. Merck, Sharp & Dohme. 1989-1990. \$21,962.
21. Biomedical Research Support Grant, NIH, Division of Research Resources. 1989-1990, \$22,489; 1990-91, \$22,896.
22. Rural Lipid Resource Center. National Heart, Lung, and Blood Institute. Principal Investigator 1989-1994. \$1,350,655.
23. PHS-DHHS, National Center for Research Resources. Minority High School Student Research Apprentice Program. 1990. \$6,000.
24. The Genetic Epidemiology of Malignant Hyperthermia. Muscular Dystrophy Association. 1990-91. \$27,000.
25. PHS-DHHS, National Center for Research Resources. Minority High School Student Research Apprentice Program. 1991. \$6,000.
26. Improving Animal Resources at The Mary Imogene Bassett Hospital. National Center for Research Resources. 1991-92. \$202,397.
27. Effects of Gemfibrozil on Postprandial Lipoprotein Levels. Parke-Davis/Warner-Lambert. \$267,355.
28. Effects of Lopid SR Administered in the Morning on Postprandial Triglyceride-Rich Lipoprotein Levels Following an Evening Meal. Parke-Davis/Warner-Lambert. \$125,343.
29. Multiple Risk Assessment in High Risk Relatives of Hospitalized Coronary Disease Patients. Parke-Davis/Warner-Lambert. \$105,559.
30. The Role of Lp(a) in Coronary Heart Disease in Blacks vs. Whites. National Heart, Lung, and Blood Institute. 1992 – 1997. \$1,599,000.
31. Dietary Effects on Lipoproteins and Thrombogenic Activity. Pennsylvania State University. National Heart, Lung, and Blood Institute. P.I. of Bassett Subcontract, Chair of Steering Committee. 1992 – 1998.
32. Distant Medical Link Grant, Rural Electrification Administration. 1993 – 1994. \$494,755.
33. A Placebo-Controlled Trial to Evaluate Endocrine Function During Pravastatin Therapy in Premenopausal Women with Hypercholesterolemia. 1993 – 1995. \$189,435.

34. Effect of Moderate Alcohol Consumption on Postprandial Clearance of Triglyceride-rich Lipoproteins. Alcoholic Beverage Medical Research Foundation. 1993 – 1995. \$70,000.
35. The Effects of Pravastatin Compared to Placebo Upon Endothelium-Dependent Coronary Blood Flow. Bristol-Myers/Squibb Co. 01/94 – 9/96. \$522,965.
36. Development and Evaluation of the Bassett Telemedicine Network. Health Resources and Services Administration, 1994 – 1997. \$1,129,455.
37. Northeast Lipid Training Center, Bristol-Myers/Squibb Co., 1994 – 1999, \$50,000-\$60,000/year.
38. Biosocial Influences on Postpartum Weight Retention. Cornell University, National Institute of Child Health and Human Development. 1/1/95 – 12/31/98, \$571,432, P.I. of Bassett Subcontract.
39. Utilization Study of Rural Hospitals. New York State Department of Health. 3/1/95 – 2/28/96.
40. Screening and Management of Cardiovascular Risk Factors in Patients with Coronary Heart Disease. American College of Cardiology, 3/1/96 – 2/28/97. \$647,082.
41. Lipid Treatment Assessment Program (L-TAP). Parke-Davis/Warner-Lambert, 8/96 – 8/97. \$7,500. Analysis Subcontract 3/1/98 – 2/28/99, \$69,000.
42. Managed Care Lipid Treatment Assessment Program (MC-L-TAP). Parke-Davis/Warner-Lambert, 3/97 – 3/98.
43. TARGET, (Treatment with Atorvastatin to Reach Goals: Evaluation of Therapy) Study. Parke-Davis/Warner-Lambert, 10/97 – 9/2000. \$75,000.
44. Nicostatin Dose-Ranging Study. KOS Pharmaceuticals, 5/1/98 – 10/30/00. \$40,800.
45. Western New York Center for Prevention of Heart Disease and Stroke. Oishei Foundation, 8/1/98 – 2/1/01. \$312,500.
46. TNT Study. Parke-Davis/Warner-Lambert, 9/1/98 – 8/30/04. \$373,000.
47. Nutrition Academic Award, HL 03943-05, National Heart, Lung, and Blood Institute, 9/30/98 – 8/31/04. \$750,000.
48. Rochester Clinical Research Curriculum Award (K30 HL 04161), National Institutes of Health, 6/1/99 – 6/31/05. \$1,000,000.
49. Cardiovascular Health Practitioners Institute, Centers for Disease Control and Prevention, 4/29/99 – 6/30/03. \$80,997 per year.

50. Research Training in Preventive Cardiology (T32 HL 07937), National Heart, Lung, and Blood Institute, 8/1/00 – 7/30/05. \$1,442,315.
51. SAFARI Trial. Merck, April 2002 – May 2003.
52. COMETS Trial. AstraZeneca, February 2003 – February 2004. \$27,500.
53. IRIS Trial. AstraZeneca, February 2003 – April 2004. \$19,915.
54. The Rochester Prevention Research Center (1U48 DP 00031), Centers for Disease Control and Prevention, September 2004 – September 2009. \$3,500,000.
55. Rochester Clinical Research Curriculum Award (K30 HL 04161), National Institutes of Health, 6/1/05-9/30/06. \$1,500,000. TDC (Continued with CTSA on 10/1/06)
56. Grenada Heart Project, World Heart Federation, 1/1/05 – 1/25/07. \$401,317 TDC
57. Research Training in Preventive Cardiology (T32 HL 07937). National Heart Lung and Blood Institute, 8/1/05-7/30/10. \$1,442,215 TDC
58. Radiology Cancer Research Training Program (R25 CA 08936), National Cancer Institute, 12/1/00-11/30/05. \$380,357 ADC.
59. Cardiovascular Health Intervention Network – Coordinating Center (2U48 DP 00031), Centers for Disease Control and Prevention, 8/31/05 – 8/30/09. \$300,000 TDC
60. Rochester Public Health – Medicine Education Center. American Association of Medical Colleges. 3/3/06 – 10/31/07. \$50,000 TDC
61. University of Rochester's Clinical and Translational Science Award. National Institutes of Health, 9/30/06-6/30/11 (1 UL1 RR024160-3; 1 KL2 RR024136-3; 1 TL1 RR024135-3). (Role: Co-Principal Investigator (2006-2009), Principal Investigator (2009-2013), Principal Investigator of Education and Training Key Function (2006-2009), Principal Investigator of the Upstate Consortium Key Function (2006-2013) \$38,800,000 TDC
62. The Rochester Prevention Research Center (U48 DP 00031), Centers for Disease Control and Prevention, 10/09-09/14. TDC: \$546,494 per year
63. The University of Rochester's Clinical and Translational Science Institute- National CTSA Educational Resource Program Supplement (NCERP) (3 UL1 RR024160-03S1), NIH/NCRR, 7/01/2008-6/30/2010. TDC: \$114,000
64. The University of Rochester's Clinical and Translational Science Institute-Collaborative Community Engagement Admin. Supplement (RICE) (3UL 1RR024160-04S1), NIH/ARRA Supplement, 9/17/09-9/16/11. TDC: \$193,821
65. The University of Rochester's Clinical and Translational Science Award (5 UL1 RR024160; 1 KL2 RR024135-5; 1 TL1 RR024135-3) NIH/NCATS 7/1/11-6/30/16 \$20,700,000 TDC

66. Research Training in Preventive Cardiology (T32 HL 07937) National Heart, Lung, and Blood Institute, 8/1/10-7/30/15. \$3,529,958 TDC.
67. CTSA Spedia (3UL1RR024160-04S2) NIH/CTSI ARRA Supplement, 9/17/09-9/16/11. \$87,837 TDC.
68. Strengthening Professionals in Comparative Effectiveness (SPICE) Workforce Development (3UL1RR024160-05S2) NIH/CTSI ARRA Supplement, 9/1/10-8/30/12. \$292,235 TDC
69. CTSA-IP Consortium Collaborative (3UL1RR024160-06S2) NIH/NCRR Supplement 7/1/11-10/31/12. \$206,520 TDC.
70. T1 Translation (3UL1RR024160-06S3) NIH/NCATS Supplement 7/1/11-6/30/12. \$500,000 TC.
71. OPENDOOR Community Engagement Program (3UL1RR024160-06S3) NIH/NCATS Supplement 7/1/11 – 6/30/12. \$500,000 TC.
72. CTSA Revision Application to Advance Evidence-based Research Related to Protection of Human Subjects. (3UL1TR000042-07S2). Informed Consent in Deaf People. 9/1/12-6/30/16. \$624,896 TC.
73. Rochester Prevention Research Center Validation of Self-Reported Sleep Surveillance. Special Interest Project (Supplement to U48DP00031). Centers for Disease Control and Prevention. 9/30/12-9/29/14. \$174,428 TC.
74. Rochester Bridges to the Doctorate for Deaf and Hard of Hearing Students. (R25 GM 107739) 9/1/13 – 9/30/13. \$250,000/yr. National Institute for General Medical Sciences.
75. Together: Transforming and Translating Discovery to Improve Health. University of Florida Clinical and Translational Science Award. PI of KL2 section (8 KL2 TR000095-07) 07/01/15 – 06/30/20. \$523,260/yr. National Center to Advance Translational Science.
76. Training Program for Applied Research and Development in Genomic Medicine. University of Florida Colleges of Pharmacy and Medicine. MPI with J. Johnson (T32 HG0080958-01A. Pending Award. \$1,423,467 TC.

**PUBLICATIONS:** (\* = Review articles)

1. Matsuda I, Pearson T, Holtzman NA. Determination of apocerulo-plasma by radioimmunoassay in nutritional copper deficiency, Menkes' kinky hair syndrome, Wilson's disease and umbilical cord blood. *Pediatr Res* 1974;8:821-4.
2. Gildersleeve DL, Pearson TA, Baghdiantz A, Foster GV. Effect of ACTH, alpha-MSH, and beta-lipotropin in calcium and phosphorus metabolism in the rabbit. *Endocrinology* 1975; 97:1593-6.
3. Pearson TA, Wang BA, Solez K, Heptinstall RH. Clonal characteristics of fibrous plaques and fatty streaks from human aortas. *Am J Pathol* 1975;81:379-87.

4. Lockwood CM, Pearson TA. Use of plasma exchange in treatment of allergic diseases. *Haemonetics Research Institutes Proceedings* 3:1975.
5. Lockwood CM, Pearson TA, Evans DJ, Peters DK, Wilson CB. Immunosuppression and plasma exchange in the treatment of Goodpasture's syndrome. *Lancet* 1976;1:711-5.
6. Pearson TA, Kramer E, Solez K, Heptinstall RH. The human atherosclerotic plaque. *Am J Pathol* 1977;86:657-64.
7. Pearson TA, Braine HG, Rathbun HK. Corynebacterium sepsis in oncology patients: Predisposing factors, diagnosis and treatment. *JAMA* 1977;238:1737-40.
8. Pearson TA, Dillman J, Kramer E, Solez K, Heptinstall RH. Clonal markers in the study of the origin and growth of human atherosclerotic lesions. *Circ Res* 1978;43:10-18.
9. Pearson TA, Dillman J, Solez K, Heptinstall RH. Clonal characteristics in layers of human atherosclerotic plaques. *Am J Pathol* 1978;93:93-102.
10. Pearson TA, Dillman J, Solez K, Heptinstall RH. Monoclonal characteristics of organising arterial thrombi: Significance in the origin and growth of human atherosclerotic plaques. *Lancet* 1979;1:7.
11. Pearson TA, Bulkley BH, Achuff SC, Kwiterovich PO, Gordis L. The association of low levels of HDL cholesterol and arteriographically-defined coronary artery disease. *Am J Epidemiol* 1979;109:285-95.
- 12.\* Pearson TA. The preventive medicine residency within the School of Public Health: Progress at Johns Hopkins. *Association of Teachers of Preventive Medicine Newsletter* 1979;26:12-13.
13. Pearson TA, Dillman J, Williams KJ, Wolff JA, Adams R, Solez K, Heptinstall RH. Clonal characteristics of experimentally induced "atherosclerotic" lesions in the hybrid hare. *Science* 1979;206:1423-5.
14. Pearson TA. Experience in teaching epidemiology and biostatistics in medical schools. *Epidemiology and Biostatistics in Clinical Cancer Education*. National Cancer Institute, 1979, pp. 23-24.
15. Pearson TA, Dillman JM, Solez K, Heptinstall RH. Evidence for two populations of fatty streaks with different roles in the atherogenic process. *Lancet* 1980;2:496-8.
16. Pearson TA, Dillman JM, Solez K, Heptinstall RH. Clonal characteristics of cutaneous scars and implications for atherogenesis. *Am J Pathol* 1981;102:49-54.
17. Naslund MJ, Pearson TA, Ritter JM. A documented episode of pulmonary vasoconstriction in systemic sclerosis. *The Johns Hopkins Medical Journal* 1981;148:78-80.
18. Pearson TA, Dillman J, Malmros H, Sternby N, Heptinstall RH. Cholesterol induced atherosclerosis: Clonal characteristics of arterial lesions in the hybrid hare. *Arteriosclerosis* 1983;3(6):574-80.



19. Pearson TA, Dillman JM, Heptinstall RH. The clonal characteristics of human aortic intima: Comparison with fatty streaks and normal media. *Am J Pathol* 1983;113:33.
- 20.\* Pearson TA. Coronary arteriography in the study of the epidemiology of CAD. *Epidemiol Rev* 1984;6:140-66.
21. Gardner TJ, Horneffer PJ, Manolio TA, Pearson TA, Gott VL, Baumgartner, WA, Borton M, Watkins L, Reitz BA. Stroke following artery bypass grafting: A ten-year study. *Ann Thorac Surg* 1985;40(6):574-81.
22. Topol EJ, Ciuffo AA, Pearson TA, Dillman J, Builder S, Grossbard E, Weisfeldt ML, Bulkley BH. Thrombolysis with recombinant tissue plasminogen activator in atherosclerotic, thrombotic occlusion. *J Am Coll Cardiol* 1985;5:85-91.
23. Raichlen JS, Healy B, Achuff SC, Pearson TA. Importance of risk factors in the angiographic progression of coronary artery disease. *Am J Cardiol* 1986;57:66-70.
24. Gardner TJ, Horneffer PJ, Manolio TA, Hoff SJ, Pearson TA. Major stroke after coronary artery bypass surgery: Changing magnitude of the problem. *J Vasc Surg* 1986;3:684-7.
25. Fried LP, Moore RD, Pearson TA. Long-term effects of cigarette smoking and moderate alcohol consumption on coronary artery diameter: Mechanisms of coronary artery disease independent of atherosclerosis or thrombosis. *Am J Med* 1986;80(1):37-44.
26. Moore RD, Pearson TA. Moderate alcohol consumption and coronary artery disease: A review. *Medicine* 1986;65:242-67.
27. Shaffer JW, Pearson TA, Mead LA, Thomas CB. A possible relationship between figure drawing data collected in medical school and later health status among physicians. *J Clin Psychol* 1986;42(2):363-9.
28. LaCroix A, Mead L, Liang K-Y, Thomas CB, Pearson TA. Coffee consumption and the incidence of coronary heart disease. *N Engl J Med* 1986;315(16):977-82.
29. Shaffer JW, Graves PL, Mead LA, Thomas CB, Pearson TA. Development of alternate methods for scoring in the Rorschach Interaction Scale. *J Educational and Psychological Measurement* 1986;46:837-44.
- 30.\* Miller RD, Pearson TA. Preventing recurrent myocardial infarction in women with coronary artery disease. *Contemporary OB/GYN*, March 1986;133-41.
31. Graves PO, Mead LA, Pearson TA. Rorschach Interaction Scale as a potential predictor of cancer. *Psychosom Med* 1986;48:549-63.
32. Becker DM, Boekeloo BO, Pearson TA. Physician recognition of CHD risk factors in high risk patients. *Md Med J* 1986;35(3):214-5.

- 33.\* Becker DM, Wilder LB, Pearson TA. Hypercholesterolemia: Nutritional and pharmacologic management. *Md Med J* 1986;35(7):549-51.
34. Becker DM, Meyers AH, Sacci M, Weida S, Swank R, Levine DM, Pearson TA. Smoking behavior and attitudes toward smoking among hospital nurses. *Am J Public Health* 1986;76(12):1449-51.
- 35.\* Pearson TA. Coronary risk factors. American Council of Life Insurance. *Medical Section Proceedings* 1986;33-46.
36. Pearson TA, Dillman JM, Heptinstall RH. Clonal mapping of the human aorta: Relationship of monoclonal characteristics, lesion thickness, and age in normal intima and atherosclerotic lesions. *Am J Pathol* 1987;126(1):33-9.
37. Herrington DM, Pearson TA. Clinical and angiographic similarities in twins with coronary artery disease. *Am J Cardiol* 1987;59(4):366-7.
38. Pearson TA, Malmros DM, Dillman J, Sternby N, Heptinstall RH. Atherosclerosis in the hypercholesterolemic hare: Comparison of coronary artery lesions induced by dietary cholesterol in the hare and the rabbit. *Atherosclerosis* 1987;63:125-35.
39. Becker LC, Becker DM, Pearson TA, Fintel DJ, Links J, Frank TL. Screening of asymptomatic sibilings of patients with premature coronary artery disease. *Circulation* 1987;75:(II)14-7.
40. Raichlen JS, Herrington DM, Healy B, Achuff SC, Pearson TA. Risk factors for progression of coronary heart disease. *Coronary Artery Disease* 1987;4(3):47-53.
41. Fried LP, Pearson TA. The association of risk factors with ateriographically defined coronary artery disease: what is the appropriate control group? *Am J Epidemiol* 1987;125:844-53.
42. Thomas J, Semanya K, Thomas CB, Thomas DG, Nesor WB, Pearson TA, Gillum RF. Precursors of hypertension in black compared to white medical students. *J Chron Dis* 1987;40:721-7.
43. Becker DM, Markakis M, Sension M, Vitalis S, Baughman K, Swank R, Kwiterovich PO, Pearson TA. Prevalence of hyperlipidemia in heart transplant recipients. *Transplantation* 1987;44(2):323-5.
44. Shaffer JW, Graves PL, Swank RT, Pearson TA. Clustering of personality traits in youth and subsequent development of cancer among physicians. *J Behav Med* 1987;10(5):441-7.
45. Horneffer PJ, Gardner TJ, Manolio TA, Hoff SJ, Rykiel RN, Pearson TA, Gott VL, Baumgartner WA, Borkon AM, Watkins L, Reitz BA. The effects of age on outcome after coronary bypass surgery. *Circulation* 1987;76,Suppl:V6-V12.
46. Boekeloo B, Becker D, Yeo E, Pearson TA, Gillilan R. Post myocardial infarction

cholesterol management by primary physicians. *J Am Coll Cardiol* 1987;9:77A.

- 47.\* Pearson TA. Multiple risk factors for coronary artery disease: Behavioral factors in preventive cardiology. *Am J Cardiol* 1987;60:74J-79J.
48. Watt P, Becker DM, Salaita K, Pearson TA. Hypercholesterolemia in patients undergoing coronary bypass surgery: Are they aware, under treatment, and under control? *Heart and Lung*, March 1988;17:2, pp. 205-8.
49. Boekeloo BO, Becker DM, DeBailly A, Pearson TA. Cholesterol management in patients hospitalized for coronary heart disease. *Am J Prev Med*, May-June 1988;4(3):128-32.
50. Moore RD, Smith CR, Kwiterovich PO, Pearson TA. Effects of low-dose alcohol use versus abstention on apolipoproteins A-1 and B. *Am J Med* 1988;84(5):884-90.
- 51.\* Trejo-Gutierrez JF, Pearson TA. A practical approach to the patient with a lipid disorder. *Modern Medicine*, November 1988;56(11):86-104.
- 52.\* Sigmund WR, Pearson TA. Omega-3 fatty acids: A review of potential benefits and clinical use. *Saudi Arabian Medical Journal* 1988;9(6):558-68.
- 53.\* Pearson TA, Boekeloo BO, Graziano S. Community based cardiovascular risk reduction programs. *Maryland Medical Journal* 1988;37(11):836-9.
54. Becker DM, Becker LC, Pearson TA, Fintel DJ, Levine DM, Kwiterovich PO. Risk factors in siblings of people with premature coronary heart disease. *J Am Coll Cardiol* 1988;12(5):1273-80.
55. Becker DM, Chamberlain B, Swank R, Hegewald MG, Baughman KL, Pearson TA, Ettinger WH, Renlund D. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. *Am J Med* 1988;85(5):632-8.
56. Greenland P, Castle CH, Cohen JD, Davidson DM, Krakoff LR, Nowacek G, Pearson TA, Riemenschneider TA, Van Citters RL, Stone EJ. Attitudes toward prevention of cardiovascular diseases among first-year students at eight American medical schools, 1983-1985. *Prev Med* 1988;17:700-11.
57. Miller RH, Horneffer PJ, Gardner TJ, Rykiel MF, Pearson TA. The epidemiology of the postpericardiotomy syndrome: A common complication of cardiac surgery. *American Heart Journal* 1988;116(5):1323-9.
58. Becker D, Becker L, Pearson T, Fintel D, Levine D, Kwiterovich P. Risk factors in siblings of people with premature coronary disease. *J Am Coll Cardiol* 1988;12(5):1273-80.
59. Pearson TA, Chanmugan P, Dillman J, Yu SO, Sternby N, Heptinstall RH. The hybrid hare as a promising model of human atherosclerosis. *Eighth International Symposium on Atherosclerosis, Workshop Sessions, Rome, Italy, October 9-13, 1989*, pp. 137-40.
- 60.\* Pearson TA. A clinical look at lipoprotein (a). *Perspectives in Lipid Disorders* 1989;6(1):15-19.

61. Manolio TA, Beattie C, Christopherson R, Pearson TA. Regional versus general anesthesia in high-risk surgical patients: The need for a clinical trial. *J Clin Anesth* 1989;1(6):414-21.
62. Coughlin SS, Szklo M, Baughan K, Pearson TA. Idiopathic dilated cardiomyopathy and atopic disease: Epidemiologic evidence for an association with asthma. *Am Heart J* 1989;118(4):768-74.
- 63.\* Pearson TA, Pyorala K. Trends in CHD in selected countries – overview. *Int J Epidemiol* 1989; 18(3) Suppl 1:S99-S100.
- 64.\* Pearson TA. Influences on CHD incidence and case fatality: Medical management of risk factors. *Int J Epidemiol* 1989;18(3) Suppl 1:S217-S222.
- 65.\* Pearson TA. LCL subclasses: A critical story unfolds. *Perspectives in Lipid Disorders* 1989.
66. Menkes MS, Matthews KA, Krantz DS, Lundberg U, Mead LA, Qaqish B, Liang K, Thomas CB, Pearson TA. Cardiovascular reactivity to the cold pressor test as a predictor of hypertension. *Hypertension* 1989;14:524-30.
67. Miller M, Mead LM, Kwiterovich PO, Pearson TA. Dyslipidemias with desirable plasma total cholesterol levels and angiographically demonstrated coronary artery disease. *Am J Cardiol* 1990;65(1):1-5.
68. Coughlin SS, Szyklo M, Baughman K, Pearson TA. The epidemiology of idiopathic dilated cardiomyopathy in a bi-racial community. *Am J Epidemiol* 1990;131(1):48-56.
69. Eaton CB, Schaad DC, Rybicki B, Pearson TA, Van Citters RL, Stone EJ, Castle CH, Cohen JD, Davidson DM, Greenland P, Krakoff LR, Reimenschneider TA, Derby C. Risk factors for cardiovascular disease in U.S. medical students: The Preventive Cardiology Academic Award Collaborative Project. In *Preventive Cardiology: Perspectives in Physician Education*. *Am J Prev Med* 1990;6(2):14-22.
70. Horneffer PJ, Miller RH, Pearson TA, Rykiel MF, Reitz BA, Gardner TJ. The effective treatment of postpericardiotomy syndrome after cardiac operations. *J Thorac Cardiovasc Surg* 1990;100:292-6.
71. Boekeloo B, Becker D, Levine D, Belitsos P, Pearson T. Strategies for increasing house staff management of cholesterol in inpatients. *Am J Prev Med* 1990;6 Suppl 1:51-9.
72. Pearson TA, LaCroix AZ, Mead LA, Liang K-Y. The prediction of midlife coronary heart disease and hypertension in young adults: The Johns Hopkins multiple risk equations. In *Preventive Cardiology: Perspectives in Physician Education*. *Am J Prev Med* 1990;6(2):23-8.
- 73.\* Pearson TA, Bowlin S, Sigmund WR. Screening for hyper-cholesterolemia. *Annu Rev Med* 1990;41:177-86.
74. Moore RD, Mead L, Pearson TA. Youthful precursors of alcohol abuse in physicians. *Am J Med* 1990;88:332-6.

75. Herrington DA, Gordon GB, Achuff SC, Trejo JF, Weissman HF, Kwiterovich PO, Pearson TA. Plasma dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS) in patients undergoing diagnostic coronary angiography. *J Am Coll Cardiol* 1990; 16:862-70.
76. Pearson TA, Jenkins GM, Thomas J. Prevention of coronary heart disease in black adults. *Cardiovascular Clinics* 1991;21(3):263-76.
- 77.\* Pearson TA. What is a risk factor and what is not – theoretical and practical implications. In *Hypertension, Lipids and Cardiovascular Disease: Is Insulin the Missing Link?* *Am J Med* 1991;90 Suppl 2A:50S-52S.
- 78.\* Steinberg D, Pearson TA, Kuller LH. Alcohol and atherosclerosis. *Ann Intern Med* 1991;114:967-76.
- 79.\* Pearson TA, Derby CA. Invited commentary: Should arteriographic case control studies be used to identify causes of atherosclerotic coronary artery disease? *Am J Epidemiol* 1991; 134:123-8.
- 80.\* Pearson TA. Guidelines for the detection and treatment of elevated serum cholesterol: Which is the baby and which is the bathwater? *Ann Intern Med* 1991;115:324-6.
81. Fried RE, Levine DM, Kwiterovich PO, Diamond EL, Wilder LB, Moy TF, Pearson TA. The effect of filtered coffee consumption on plasma lipids. *JAMA* 1992;267:811-5.
82. Olson SH, Kelsey JL, Pearson TA, Levin B. Evaluation of random digit dialing as a method of control selection in case-control studies. *Am J Epidemiol* 1992;135:210-22.
- 83.\* Pearson TA. Coronary intervention trials: Unsolved questions. *Clinics in Applied Nutrition* 1992;2:9-17.
- 84.\* Manolio TA, Baughman KL, Rodeheffer R, Pearson TA, et al. The prevalence and etiology of idiopathic dilated cardiomyopathy: Summary of an NHLBI workshop. *Am J Cardiol* 1992;69:1458-66.
- 85.\* Francis CA, Dustan HP, Haywood JL, Pearson TA, Wenneker MB. Scope of the problem, 23<sup>rd</sup> Bethesda conference: Access to cardiovascular care. *J Am Coll Cardiol* 1992;19:1441-60.
86. Miller M, Seidler A, Kwiterovich PO, Pearson TA. Long-term predictors of subsequent cardiovascular events in men with coronary artery disease and a “desirable” level of plasma total cholesterol. *Circulation* 1992;86:1165-70.
- 87.\* Manolio TA, Pearson TA, Wenger NK, Barrett-Connor E, et al. Cholesterol and heart disease in older persons and women. *Annals of Epidemiology* 1992;2:161-76.
88. Kwiterovich PO, Coresh J, Smith H, Bachorik PS, Derby C, Pearson T. A comparison of the plasma levels of apolipoproteins B and A-1 and other risk factors in men and women with premature coronary atherosclerosis. *Am J Cardiol* 1992;69:1015-21.

- 89.\* Pearson TA. Therapeutic management of triglycerides: An international perspective. *Am J Cardiol* 1992;70(19):26H-31H.
90. Kris-Etherton PM, Derr J, Mitchell DC, Russell MR, Mustad VA, McDonnell ET, Pearson TA. The role of fatty acid saturation on plasma lipids, lipoproteins, and apolipoproteins: I. Effects of whole food diets high in cocoa butter, olive oil, soybean oil, dairy butter, and milk chocolate on the plasma lipids of young men. *Metabolism* 1993;42:121-9.
91. Derr J, Kris-Etherton PM, Pearson TA, Seligson FH. The role of fatty acid saturation on plasma lipids, lipoproteins, and apolipoproteins: II. The plasma total and LDL-cholesterol response of individual fatty acids. *Metabolism* 1993;42:130-4.
92. Mustad VA, Kris-Etherton PM, Derr J, Reddy CC, Pearson TA. Comparison of the effects of diets rich in stearic acid versus myristic acid and lauric acid on platelet fatty acids and excretion of thromboxane A<sub>2</sub> and PGI<sub>2</sub> metabolites in healthy young men. *Metabolism* 1993;42:463-9.
- 93.\* Pearson TA, Patel RJ. The quest for a cholesterol-decreasing diet: Should we subtract, substitute, or supplement. *Ann Intern Med* 1993;119:627-8.
94. Bowlin SJ, Morrill BD, Nafziger AN, Jenkins PL, Lewis CL, Pearson TA. Validity of cardiovascular disease risk factors assessed by telephone survey: The behavioral risk factor survey. *J Clin Epidemiol* 1993;46:561-71.
95. Klag MJ, He K, Mead LA, Ford DE, Pearson TA, Levine DM. Validity of physicians' self-reports of cardiovascular disease risk factors. *Annals of Epidemiology* 1993;3:442-7.
- 96.\* Pearson TA, Marx HJ. Editorial: The rapid reduction in cardiac events with lipid-lowering therapy: mechanisms and implications. *Am J Cardiol* 1993;72:1072-3.
- 97.\* Pearson TA, Brown VW, Donato K, et al. Lipids. Report of the AHA Prevention Conference III. *Circulation* 1993;88:1375-1407.
- 98.\* Bild DE, Williams RR, Brewer HB, Herd JA, Pearson TA, et al. Identification and management of heterozygous familial hypercholesterolemia: Summary and recommendations from an NHLBI workshop. *Am J Cardiol* 1993;72:1D-5D.
99. Pearson TA. Diagnosis and case finding in familial hypercholesterolemia. *Am J Cardiol* 1993;72:15D-17D.
100. Pearson TA, Heiss G, Eds. Atherosclerosis: Quantitative imaging, risk factors, prevalence, and change. *Circulation* 1993;87 Suppl II:2-82.
101. Klag MJ, Mead LA, LaCroix AZ, Liang K-Y, Pearson TA, Levine DM. Coffee intake and coronary heart disease. *Annals of Epidemiology* 1994;4:425-33.
102. Dennison BA, Jenkins PL, Pearson TA. Challenges to implementing the current pediatric cholesterol screening guidelines into practice. *Pediatrics* 1994;94:296-302.

103. Eaton CB, Strogatz D, Nafziger A, Pearson TA. Self-reported physical activity in a rural county: A New York county health census. *Am J Public Health* 1994;84(1):29-32. [PMCID: PMC1614925](#)
104. Kris-Etherton PM, Derr JA, Mustad VA, Seligson FH, Pearson TA. Effects of a milk chocolate bar per day substituted for a high-carbohydrate snack in young men on an NCEP/AHA step-one diet. *Am J Clin Nutr* 1994;60:1037S-1042S.
105. Olson SH, Kelsey JL, Pearson TA, Levin B. Characteristics of a hypothetical group of hospital controls for a case-control study. *Am J Epidemiol* 1994;139:302-11.
106. Ammerman A, Caggiula A, Elmer P, Kris-Etherton P, Pearson TA, et al. Putting medical practice guidelines into practice: The cholesterol model. *Am J Prev Med* 1994;10(4):209-16.
- 107.\* Goldstein S, Pearson TA, et al. The relationship between cardiovascular specialists and generalists. ACC Bethesda Conference Report, "Future Personnel Needs in Cardiovascular Health Care". *J Am Coll Cardiol* 1994;24(2):304-12.
108. Reed RG, Jenkins P, Pearson TA. Laboratory's manner of reporting serum cholesterol affects clinical care. *Clinical Chemistry* 1994;40:847-8.
- 109.\* Pearson TA, Rappaport E, Criqui M, et al. Optimal risk factor management in the patient following coronary revascularization. *Circulation* 1994;90:3125-33.
- 110.\* Pearson TA, Terry P. The clinician's conundrum: What to advise patients about drinking alcohol. *JAMA* 1994;272:967-8.
- 111.\* Philbin EF, Pearson TA. How does lipid-lowering therapy rapidly reduce ischemic events? *Journal of Myocardial Ischemia* 1994;6(10):13-8.
- 112.\* Swan HJC, Brown J, Davidson MH, Gibbons RJ, Levy D, Meijler FL, Pasternak RC, Pearson TA, Rosenman RH. Preventive cardiology and atherosclerotic disease. *J Am Coll Cardiol* 1994;24(3):838.
113. Reed RG, Fong SY, Pearson TA. The role of a central laboratory in implementing the national cholesterol education panel guidelines in rural practices: A model system of managed care. *Clinical Chemistry* 1995;41/2:271-4.
114. Sturgeon SR, Schairer C, Brinton LA, Pearson TA, Hoover RN. Evidence of a healthy estrogen user survivor effect. *Epidemiology* 1995;6(3):227-31.
- 115.\* Mathew J, Pearson TA. Clinical and epidemiologic predictors of recurrent coronary artery disease. *Coronary Artery Disease* 1995;6(6):447-56.
116. Pearson TA, Spencer M, Jenkins P. Who will provide preventive services? The changing relationships between medical care systems and public health agencies in health care reform. *Journal of Public Health Management & Practice* 1995;1:16-27.
- 117.\* Pearson TA. Multinational study results and implications for cardiovascular risk management. *Clinical Issues in Hyperlipidemia* 1995;2(7).

- 118.\* Smith SC, Blair SW, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. *Circulation* 1995;92:2-4.
- 119.\* Smith SC, Blair SW, Criqui MH, et al. Preventing heart attack and death in patients with coronary disease. *J Am Coll Cardiol* 1995;26:292-4.
- 120.\* Marx HJ, Pearson TA. Lipid disorders in the elderly should be managed. *Pro. Coronary Artery Disease Index and Reviews* 1995;1(6):4, 18-9.
- 121.\* Pearson TA, Swan HJC. Lipid lowering. The case for identifying and treating the high-risk patient. *Cardiology Clinics* 1996;14:117-30.
- 122.\* Pearson TA, Fuster V. Executive summary. ACC Bethesda Conference Report, 27<sup>th</sup> Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. *J Am Coll Cardiol* 1996;27:961-3.
- 123.\* Pearson TA, McBride P, Houston-Miller N, Smith S. Organization of preventive cardiology service. ACC Bethesda Conference Report, 27<sup>th</sup> Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. *J Am Coll Cardiol* 1996;27:1039-47.
124. Bowlin SJ, Morrill BD, Nafziger AN, Lewis C, Pearson TA. Reliability and changes in validity of self-reported cardiovascular disease risk factors using dual response: The behavioral risk factor survey. *J Clin Epidemiol* 1996;49:511-7.
125. Pearson TA. Cholesterol screening in asymptomatic adults. No cause to change. Task Force on Risk Reduction, American Heart Association. *Circulation* 1996;93:1067-78.
126. Mustad V, Derr J, Channa Reddy C, Pearson TA, Kris-Etherton PM. Seasonal variation in parameters related to coronary heart disease risk in young men. *Atherosclerosis* 1996;126:117-29.
- 127.\* Pearson TA. Cardiovascular diseases as a growing health problem in developing countries: the role of nutrition in the epidemiologic transition. *Public Health Reviews* 1996;24:131-46.
- 128.\* Grundy SM, Pearson TA. Guidelines for using serum cholesterol, HDL-C, and TG levels as screening tests in adults. *Abstracts of Clinical Care Guidelines* 1996;8:5-6.
129. Myerson M, Pearson TA. Management of cardiovascular risk factors: An integral part of the patient with atherosclerotic disease. ACC Educational Highlights, Fall 1996, pp. 16-21.
130. Krauss RM, Deckelbaum RJ, Ernst N, Fisher D, Howard BV, Knopp RH, Kotchen T, Lichtenstein AH, McGill HC, Pearson TA, Prewitt TE, Stone NJ, Horn CV, Weinberg R. Dietary guidelines for healthy American adults. A statement for health professionals from the Nutrition Committee, American Heart Association. *Circulation* 1996;94:1795-1800.
- 131.\* Pearson TA. Alcohol and heart disease. *Circulation* 1996;94:3023-5.
132. Pinkowish MD, Cohen JD, Pearson TA, Weart CW. Cholesterol update: Who really



needs cholesterol-lowering drugs? *Patient Care* 1996;30:92-108.

- 133.\* Philbin EF, Ries MD, Groff GD, Sheesley KA, French TS, Pearson TA. Osteoarthritis as a determinant of an adverse coronary heart disease risk profile. *Journal of Cardiovascular Risk* 1996;3:529-33.
134. Philbin EF, Ries MD, Groff GD, Sheesley KA, Baker SL, Pearson TA. Coronary heart disease risk factors after total joint arthroplasty of the hip and knee. *Journal of Orthopaedic Rheumatology* 1996;9:200-7.
- 135.\* Pearson TA, LaCava J, Weil HFC. Epidemiology of thrombotic/hemostatic factors and their associations with cardiovascular disease. *Am J Clin Nutr* 1997;1674S-1682S.
- 136.\* Bowlin SJ, Medalie JH, Pearson TA. Cholesterol and vascular disease in the elderly. *Nutrition, Health and Aging* 1997;1:51-61.
- 136a. Bowlin SJ, Medalie JH, Pearson TA. Cholesterol and vascular disease in the elderly. *Facts and Research in Gerontology* 1996.
137. Mustad V, Etherton TD, Cooper AD, Mastro A, Pearson TA, Jonnalagadda SS, Kris-Etherton PM. Reducing saturated fat intake is associated with increasing levels of LDL receptors on mononuclear cells in healthy men and women. *J Lipid Res* 1997;38(3):459-68.
138. Gelber AC, Klag MJ, Mead LA, Thomas JD, Pearson TA, et al. Gout and risk for subsequent coronary heart disease: The Meharry-Hopkins Study. *Arch Intern Med* 1997;157:1436-40.
139. Mosca L, Rubenfire M, Mandel C, Rock C, Tarshis T, Mandel C, Tsai A, Pearson TA. Antioxidant nutrient supplement reduces the susceptibility of low density lipoprotein to oxidation in patients with coronary heart disease. *J Am Coll Cardiol* 1997;30(2):392-9.
140. Mosca L, Rubenfire M, Tarshis T, Mandel C, Tsai A, Pearson TA. Clinical predictors of oxidized low-density lipoprotein in patients with coronary artery disease. *Am J Cardiol* 1997;80(7):825-30.
- 141.\* Pearson TA, Peters TD. The treatment gap in coronary heart disease and heart failure: Community standards and the post-discharge patient. *Am J Cardiol* 1997;80(8B):45H-54H.
- 142.\* Pearson TA. Global perspectives on cardiovascular disease (editorial). *Evidence Based Cardiovascular Medicine* 1997;1(1):4-6.
- 143.\* Grundy SM, Balady AJ, Criqui MH, Fletcher G, Greenland P, Hirataka LF, Houston-Miller N, Kris-Etherton PM, Krumholz HM, LaRosa J, Ochene IS, Pearson TA, Reed J, Smith SC, Washington R. Guide to primary prevention of cardiovascular diseases: A statement for healthcare professionals from the task force of risk reduction. *Circulation* 1997;95:2329-31.
- 144.\* LaRosa JC, Pearson TA. Cholesterol screening guidelines: Consensus, evidence, and the departure from common sense. *Circulation* 1997;95:1651-3.
- 145.\* Pearson TA, Myerson M. Treatment of hypercholesterolemia in women: Equality, effectiveness, and extrapolation of evidence (editorial). *JAMA* 1997;277:1320-1.

146. Thomas J, Thomas J, Pearson T, Klag M, Mead L. Cardiovascular disease in African American and white physicians: The Meharry cohort and Meharry-Hopkins cohort studies. *Journal of Health Care for the Poor and Underserved* 1997;8:271-84.
- 147.\* Grundy SM, Balady AJ, Criqui MH, Fletcher G, Greenland P, Hirataka LF, Houston-Miller N, Kris-Etherton PM, Krumholz HM, LaRosa J, Ochene IS, Pearson TA, Reed J, Smith SC, Washington R. When to start cholesterol lowering therapy in patients with coronary heart disease. *Circulation* 1997;95:1683-5.
- 148.\* Pearson TA, Stone EJ. Executive summary: community trials for cardiopulmonary health: directions for public health practice, policy, and research. *Ann Epidemiol* 1997;S7:S1-S3.
- 149.\* Stone EJ, Pearson TA, Fortmann SP, McKenlay JB. Community based prevention trials: Challenges and directions for public health practice, policy, and research. *Ann Epidemiol* 1997;S7:S113-S120.
- 150.\* Pearson TA, AHA Science Advisory. Alcohol and heart disease. Nutrition Committee of the American Heart Association. *Am J Clin Nutr* 1997;65:1567-9.
- 151.\* Myerson M, Pearson TA. Cholesterol-lowering drugs. *Cardiology Clinics* 1997;1:159-80.
- 152.\* Konstam MA, Pearson TA, Roberts WC, Smith SC. Symposium summary remarks. *Am J Cardiol* 1997;80(8B):89H-90H.
153. Lefevre M, Ginsberg HN, Kris-Etherton PM, Elmer PJ, Stewart PW, Ershow A, Pearson TA, Roheim PS, Ramakrishnan R, Derr J, Gordon DJ, Reed R. ApoE genotype does not predict lipid response to changes in dietary saturated fatty acids in a heterogeneous normolipidemic population. *Arteriosclerosis, Thrombosis, and Vascular Biology* 1997;17(11):2914-23.
154. Schwartz RG, Pearson TA. Can single photon emission computed tomography myocardial perfusion imaging monitor the potential benefit of aggressive treatment of hyperlipidemia? *Journal of Nuclear Cardiology* 1997;4(6):555-68.
- 155.\* Pearson TA, Feinberg W. Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease. *Annals of Behavioral Medicine* 1997;19(3):230-8.
- 156.\* Bowlin SJ, Medalie JH, Pearson TA. Cholesterol and vascular disease in the elderly. In: *Facts, Research and Intervention in Geriatric Serie. Supplement: Vascular Diseases. Vascular Diseases in the Elderly.* ed: Vellas B, Albarade JL, Garry PJ. Serdi Publisher, Paris. 1997:25-47.
- 157.\* Pearson TA. Strategies to improve risk factor management. *Cardiology in Review/ Cardiology in General Practice* 1997.
158. Mosca L, Sievers J, Rubenfire M, Maimon E, Rock C, Tsai A, Pearson TA. Reduced dietary folate intake is associated with increased levels of oxidized low-density lipoprotein in patients with coronary artery disease. *Preventive Cardiology* 1998;2:11-8.

159. Nafziger AN, Bowlin SJ, Jenkins PL, Pearson TA. Longitudinal changes in dehydroepiandrosterone concentrations. *J Lab Clin Med* 1998;131:316-23.
160. Ginsberg HN, Dennis B, Elmer PJ, Ershow A, Lefevre M, Pearson TA, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: DELTA Protocol-1. *Arteriosclerosis, Thrombosis, and Vascular Biology* 1998;18(3):441-9.
- 161.\* Werner R, Pearson TA. What's so passive about passive smoking? *JAMA* 1998;279(2):157-8.
- 162.\* Werner RM, Pearson TA. LDL cholesterol: A risk factor for coronary artery disease – from epidemiology to clinical trials. *Can J Cardiol* 1998;14 Suppl B:1B-8B.
- 163.\* Davignon J, Pearson TA. Beyond LDL-cholesterol: Can further reductions in CAD risk be achieved by considering triglycerides? *Can J Cardiol* 1998;14 Suppl B:2B.
164. Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: The Baltimore coronary observational long-term study. *J Am Coll Cardiol* 1998;31:1252-7.
165. Anand SS, Enas EA, Pogue J, Haffner S, Pearson TA, Yusuf S. Elevated lipoprotein (a) levels in South Asians in North America. *Metabolism* 1998;47(2):182-4.
- 166.\* Pearson TA, Smith SC, Poole-Wilson P. Cardiovascular specialty societies and the emerging global burden of cardiovascular disease: A call to action. *Circulation* 1998;97(6):602-4.
- 167.\* Liebson PR, Drenthen T, Fullard E, Kottke TE, Fowler G, Beaglehole R, Pearson TA, et al. Facilitating preventive cardiology practices in primary care: An international perspective. *Preventive Cardiology* 1998;1:46-52.
- 168.\* Pearson TA. Lipid-lowering therapy in low-risk patients. *JAMA* 1998;279(20):1659-61.
169. Lewis C, Duncan LE, Balance DI, Pearson TA. Is sexual dysfunction in hypertensive women uncommon or understudied? *Am J Hypertens* 1998;11(6):733-5.
- 170.\* Grundy SM, Balady GJ, Criqui MH, Fletcher G, Greenland P, Hiratzka LF, Houston-Miller N, Kris-Etherton PM, Krumholz HM, LaRosa J, Ockene IS, Reed J, Pearson TA, Washington R, Smith SC. Primary prevention of coronary heart disease: Guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. *Circulation* 1998;97:1876-87.
171. Pearson TA, Lewis C. Rural epidemiology: Insights from a rural population laboratory. *Am J Epidemiol* (Columbia University School of Public Health Special 75<sup>th</sup> Anniversary Issue) 1998;148(10):949-57.
172. Record NB, Harris DE, Gipson GW, DeSisto M, Pearson TA. Physician attitude versus patient outcome: Lipid care for veterans with coronary disease. *Federal Practitioner* 1998;15(7):61-76.
173. Harris DE, Record NB, Gipson GW, Pearson TA. Lipid lowering in a multidisciplinary

- clinic compared to primary physician management. *Am J Cardiol* 1998;81(7):929-33.
174. Record NB, Harris DE, Gipson GW, DeSisto M, Pearson TA. Gaps in physician lipid care and outcomes: Physicians continue to face the challenge of improving lipid-lowering strategies to meet national goals for lowered cholesterol. *Federal Practitioner* July,1998:61-76.
- 175.\* Pearson TA, Lester ML. Commentary: Ecological study of reasons for sharp decline in mortality from ischemic heart disease in Poland since 1991. *Evidence-Based Cardiovascular Medicine* 1998;2(3):72.
- 176.\* Pearson TA, Bales VS, Blair L, Emmanuel SC, Farquhar JW, Low LP, MacGregor LJ, MacLean DR, O'Connor B, Pardell H, Petrasovits A. The Singapore Declaration: Forging the will for heart health in the next millennium. *CVD Prevention* 1998;1(3):182-99.
- 177.\* Lester ML, Pearson TA. Revisited: The nonpharmacologic strategies to treat lipid disorders. *Strategic Medicine* 1998;2(9):33-8.
178. Naglak M, Mitchell DC, Kris-Etherton P, Harkness W, Pearson TA. What to consider when conducting a cost-effectiveness analysis in a clinical setting. *J Am Diet Assoc* 1998;98(10):1149-54.
- 179.\* Pearson TA. Primary and secondary prevention of coronary artery disease: Trials of lipid lowering with statins. *Am J Cardiol* 1998;82:28S-30S.
- 180.\* Pearson TA. From science to strategy in heart health. *CVD Prevention* 1998;1:328-35.
181. Weinehall L, Westman G, Hellsten G, Boman K, Hallmans G, Pearson TA, Wall S. Shifting the distribution of risk: Results of a community intervention in a Swedish program for the prevention of cardiovascular disease. *J Epidemiol Community Health* 1999;53(4):243-50. [PMCID: PMC1756863](#)
- 182.\* Mosca LJ, King K, Limacher M, Oparil S, Pasternak R, Pearson TA, Redberg R, Smith S, Zinberg S, Young H, Judelson DR, Mills K, Bannister L, Winston M. A guide to preventive cardiology in women. *Circulation* 1999;99:2480-4.
183. Mustad VA, Jonnalagadda SS, Behr SR, Pearson TA, Kris-Etherton PM. Comparative cholesterolemic response to solid food diets and defined liquid formula diets. *Am J Clin Nutr* 1999;70:839-46.
- 184.\* Mosca L, Grundy SM, Judelson D, King K, Limacher M, Oparil S, Pasternak R, Pearson TA, Redberg R, Smith S, Winston M, Young G, Zinberg S. AHA/ACC Medical/Scientific Consensus Panel Statement: A guide to preventive cardiology for women. *J Am Coll Cardiol* 1999;33(6):1751-5.
- 185.\* Pearson TA. Blood pressure control after the onset of coronary artery disease. *The Hypertension Letter: A Medical Service from Les Laboratoires Servier* 1999;34:2-3.
- 186.\* Pearson TA. Guidelines for cardiovascular disease prevention: The approaches in the United States versus Europe. *Journal of the Israel Heart Society* 1999;9(2):14-7.

- 187.\* Pearson TA. Matching intensity of intervention with risk for coronary events: Targets for LDL-C, HDL-C, and other risk factors. *Preventive Cardiology* 1999;2:11-7.
188. Kris-Etherton PM, Pearson TA, Wan Y, Hargrove RL, Moriarty K, Fishell V, Etherton TD. High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. *Am J Clin Nutr* 1999;70(6):1009-15.
- 189.\* Pearson TA, Bloch R, Dorantes J, Fang C, Gordian A, Swanson J, Brown KL. The rationale for renewed interest by physicians in nutrition. *Current Atherosclerosis Reports* 1999;1:173-5.
- 190.\* Pearson TA. Cardiovascular disease in developing countries: Myths, realities, and opportunities. *Cardiovascular Drugs and Therapy* 1999;13:95-104.
191. Pearson TA. Epidemiology of HDL cholesterol as a risk factor for coronary heart disease. *CME Supplement to Am J Cardiol* 1999.
192. Yu-Poth S, Etherton TD, Reddy CC, Pearson TA, Reed R, Zhao G, Jonnalagadda S, Wan Y, Kris-Etherton PM. Lowering dietary saturated fat and total fat reduces the oxidative susceptibility of low density lipoprotein in healthy men and women. *J Nutr* 2000;130(9):2228-37.
193. Reed RG, Kris-Etherton PM, Stewart PW, Pearson TA. for the DELTA Investigators: Variation of lipids and lipoproteins in premenopausal women compared to men and postmenopausal women. *Metabolism* 2000;49(9):1101-5.
194. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving NCEP Target LDL-C goals. *Arch Intern Med* 2000;160:459-67.
- 195.\* Pearson TA, Bloch R, Dorantes J, Fang C, Gordian A, Swanson J, Brown K. Guidelines for cardiovascular risk reduction. *Primary Care Special Edition* 2000;4:17-29.
196. Duncan LE, Lewis C, Jenkins P, Pearson TA. Does hypertension and its pharmacotherapy affect the quality of sexual function in women? *Am J Hypertens* 2000;13:640-7.
- 197.\* Boden WE, Pearson TA. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. *Am J Cardiol* 2000;85:645-50.
198. Paultre F, Pearson TA, Weil HFC, Tuck CH, Myerson M, Rubin J, Francis CK, Marx HF, Philbin EF, Reed RG, Berglund L. High levels of lipoprotein(a) with a small apolipoprotein(a) isoform are associated with coronary artery disease in both African American and Caucasian men. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2000;20(12):2619-24.
- 199.\* Pearson TA. Population benefits of cholesterol reduction: Epidemiology, economics, and ethics. *Am J Cardiol* 2000;85:20E-23E.
200. Pearson TA. Scandinavia's lessons to the world of public health. (Editorial). *Scandinavian Journal of Public Health* 2000;28(3):161-3.

- 201.\* Foot DK, Lewis RP, Pearson TA, Beller GA. Demographics and cardiology, 1950 – 2050. *J Am Coll Cardiol* 2000;35(5B):66B-80B.
202. Grundy SM, Bazzarre T, Cleeman J, D'Agostino RB Sr, Hill M, Houston-Miller N, Kannel WB, Krauss R, Krumholz HM, Lauer RM, Ockene IS, Pasternak RC, Pearson TA, Ridker PM, Wood D. Prevention Conference V: Beyond secondary prevention: Identifying the high-risk patient for primary prevention: Medical office assessment: Writing Group I. *Circulation* 2000;101(1):E3-E11.
- 203.\* Pearson TA. The undertreatment of LDL-cholesterol: Addressing the challenge. *Am J Cardiol* 2000;74 Suppl 1:S23-S28.
- 204.\* Pearson TA, Bloch R, Dorantes J, Fang C, Gordian A, Swanson J, Brown KL. Guidelines for cardiovascular risk reduction. *Cardiology Special Edition* 2000;6:31-41.
- 205.\* Pearson TA, Pashkow FJ. Lowering LDL in patients with heart disease: How aggressive should you be? *Cleveland Clinic Journal of Medicine* 2000;67:489-96.
206. Kris-Etherton PM, Stewart PW, Lefevre M, Dennis BH, Elmer PJ, Ginsberg HN, Robeim PS, Tracy PR, Berglund L, Ershow AG, Mustad V, Jonnalagadda S, Phippips K, Ramakrishnan R, Reed R, Yu-Poth S, Ingram-Smith C, Coval SM, Pearson TA, for the DELTA Research Group. Diet effects on factor VII<sub>c</sub> are mediated by changes in plasma lipids and lipoproteins. Submitted to *Am J Clin Nutr* 2000.
207. Philbin EF, Weil FC, Francis CA, Marx HJ, Jenkins PL, Pearson TA, Reed RG. Race-related differences among patients with LV dysfunction: Observations from a biracial angiographic cohort. *Journal of Cardiac Failure* 2000;6(3):187-93.
208. Naglak MC, Mitchell DC, Shannon BM, Pearson TA, Harkness WL, Kris-Etherton PM. Nutrient adequacy of the diets of hypercholesterolemic adults following cholesterol-lowering intervention: Long-term assessment. *J Am Diet Assoc* 2000;100:1385-8.
209. Kris-Etherton PM, Stewart PW, Dennis BH, Elmer PJ, Ginsberg HN, Lefevre M, Ershow AG, Derr J, Jonnalagadda S, Mustad V, Rajasekhar R, Reed R, Roheim PS, Tracy RP, Yu S, Pearson TA, for the DELTA Research Group. Biologic covariation between changes in plasma lipids and Factor VII<sub>c</sub>: the greatest factor VII<sub>c</sub> decrease is associated with the largest total cholesterol and triglyceride lowering. Submitted.
210. Cooper R, Cutler J, Desvigne-Dickens P, Fortmann SP, Friedmann L, Havlik R, Hogelin G, Manolio T, Marler J, McGovern P, Morosco G, Mosca L, Pearson T, Stamler J, Stryer D, Thom T. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the national conference on CVD prevention. *Circulation* 2000;102:3137-47.
- 211.\* Meagher EA, Oz MC, Pearson TA. Do antioxidants prevent heart disease? *Patient Care* 2000;34(12):74-93.
- 212.\* Pearson TA, Boden WE. The imperative to raise low HDL-cholesterol. Evolving a better clinical strategy for the prevention and treatment of CHD. *Am J Cardiol* 2000;86:1-4.

- 213.\* Pearson TA. Divergent approaches to the treatment of dyslipidemia with low HDL-C. *Am J Cardiol* 2000;86 Suppl:57L-61L.
214. Eichelberger JP, Velarde G, Gajary E, McDermott MP, Pearson TA. Long term follow up of patients treated with fenfluramine/phentermine: Low incidence of cardiac outcomes despite increased cardiac valvular abnormalities. Submitted to *N Engl J Med*, December, 2000.
- 215.\* Kris-Etherton P, Pearson TA. Over-the-counter statin medications: Emerging opportunities for RDs. *J Am Diet Assoc* 2000;100(10):1126-30.
- 216.\* Pearson TA. Today's children, tomorrow's parents: A global view of the pediatric roots of the cardiovascular disease epidemic. *CVD Prevention* 2000;3(2):102-5.
217. Houghton JL, Pearson TA, Reed RG, Torosoff MT, Henches NL, Kuhner PA, Philbin EF. Cholesterol lowering with pravastatin improves resistance artery endothelial function: report of six subjects with normal coronary angiograms. *Chest* 2000;118:756-60.
- 218.\* Pearson TA, Osorio D, Brown K. Nutritional interventions in cardiovascular disease: New challenges and opportunities. *Current Atherosclerosis Reports* 2000;2:515-20.
- 219.\* Goldschmidt J, Pearson TA. Improving your patient's lipid profile. *Resident & Staff Physician* 2001;47(5):42-50.
220. Pearson TA, Lewis C, Wall S, Jenkins PL, Nafziger A, Weinehall L. Dissecting "the black box" of community intervention: Background and rationale. *Scandinavian Journal of Public Health* 2001;29 Suppl 56:5-12.
221. Nafziger AN, Erb TA, Jenkins PL, Lewis C, Pearson TA. The Otsego-Schoharie Healthy Heart Program: Prevention of cardiovascular disease in the rural United States. *Scandinavian Journal of Public Health* 2001;29 Suppl 56:21-32.
222. Nafziger AN, Weinehall L, Lewis C, Jenkins PL, Erb TA, Pearson TA, Wall S. Design issues in the combination of international data from two rural community cardiovascular intervention programs. *Scandinavian Journal of Public Health* 2001;29 Suppl 56:33-9.
223. Jenkins PL, Weinehall L, Erb TA, Lewis C, Nafziger AN, Pearson TA, Wall S. The Norsjo/Otsego-Schoharie Healthy Heart Project: A case study in combining data from different studies without the use of meta-analysis. *Scandinavian Journal of Public Health* 2001; 29 Suppl 56:40-5.
224. Weinehall L, Lewis C, Nafziger AN, Jenkins PL, Erb TA, Pearson TA, Wall S. Different outcomes for different intervention focus: A cross-country comparison of community interventions in rural Swedish and U.S. populations. *Scandinavian Journal of Public Health* 2001; 29 Suppl 56:46-58.
225. Pearson TA, Wall S, Lewis C, Jenkins P, Nafziger A, Weinehall L. Dissecting the "Black Box" of community intervention: Lessons from community-wide cardiovascular disease prevention program in the United States and Sweden. *Scandinavian Journal of Public Health* 2001;

29 Suppl 56:69-78.

226. Hargrove RL, Etherton TD, Pearson TA, Harrison EH, Kris-Etherton PM. Low-fat and high MUFA diets decrease LDL oxidation in vitro. *J Nutr* 2001;131:1758-63.
227. Duncan LE, Lewis C, Smith CE, Jenkins P, Nichols M, Pearson TA. Sex, drugs, and hypertension: A methodological approach for studying a sensitive subject. *International Journal of Impotence Research* 2001;13:31-40.
228. Kris-Etherton P, Eissenstat B, Jaax S, Srinath U, Scott L, Rader J, Pearson TA. Validation for MEDFACTS, a dietary assessment instrument for evaluating adherence to total and saturated fat recommendations of the National Cholesterol Education Program Step 1 and Step 2 diets. *J Am Diet Assoc* 2001;101:81-8.
229. Swanson JR, Pearson TA. Screening family members at high risk for coronary disease: Why isn't it done? *Am J Prev Med* 2001;20(1):50-5.
230. Verdecchia P, Porcellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson TA, Ambrosio G. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. *Circulation* 2001;104:2039-44.
- 231.\* Kris-Etherton P, Daniels SR, Eckel RH, Engler M, Howard BV, Krauss RM, Lichtenstein AH, Sacks F, St. Jeor S, Stampfer M, Grundy SM, Appel LJ, Byers T, Campos H, Cooney G, Denke MA, Kennedy E, Marckmann P, Pearson TA, Riccardi G, Rudel LL, Rudrum M, Stein DT, Tracy RP, Ursin V, Vogel RA, Zock PL, Bazzarre TL, Clark J. AHA scientific statement: Summary of the Scientific Conference on Dietary Acids and Cardiovascular Health. Conference summary from the Nutrition Committee of the American Heart Association. *J Nutr* 2001;131(4):1322-6.
- 232.\* Kris-Etherton P, Daniels SR, Eckel RH, Engler M, Howard BV, Krauss RM, Lichtenstein AH, Sacks F, St. Jeor S, Stampfer M, Grundy SM, Appel LJ, Byers T, Campos H, Cooney G, Denke MA, Kennedy E, Marckmann P, Pearson TA, Riccardi G, Rudel LL, Rudrum M, Stein DT, Tracy RP, Ursin V, Vogel RA, Zock PL, Bazzarre TL, Clark J. Summary of the scientific conference on dietary fatty acids and cardiovascular health: Conference summary from the nutrition committee of the American Heart Association. *Circulation* 2001;103(7):1034-9.
- 233.\* Chirieac D, Pearson TA. Detection and management of hyperlipidemia in the elderly. *Cardiology Review* 2001;18(10):25-32.
- 234.\* Pearson TA. Capacity for research in minority health: The need for infrastructure plus will. *Am J Med Sci* 2001;322(5):243-7.
235. Pearson TA, Stone EJ, Grundy S, McBride P, Van Horn L, and the NAA Collaborative Group. Translation of nutritional sciences into medical education: The Nutritional Academic Award Program. *Am J Clin Nutr* 2001;74:164-70.
- 236.\* Pearson TA. Nutritional interventions to reduce cardiovascular disease: Individual versus population perspectives. *Current Atherosclerosis Reports* 2001;3:425-7.



- 237.\* Smith Jr. SC, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson TA, Pfeffer MA, Starke RD, Taubert KA. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. *Circulation* 2001;104:1577-9.
238. Rubin J, Pearson TA, Reed RG, Berglund L. Fluorescence-based, nonradioactive method for efficient detection of the pentanucleotide repeat (TTTTTA)<sub>n</sub> polymorphism in the apolipoprotein (a) gene. *Clin Chem* 2001;47(10):1758-62.
239. Rubin J, Paultre F, Tuck CH, Holleran S, Reed RG, Pearson TA, Thomas CM, Ramakrishnan R, Berglund L. Apolipoprotein (a) genotype influences isoform dominance pattern differently in African Americans and Caucasians. *Journal of Lipid Research* 2002;43:234-44.
- 240.\* Pearson TA. New tools for coronary risk assessment: What are their advantages and limitations? *Circulation* 2002;105:886-92
- 241.\* Pearson TA, Blair SN, Daniels SR, Edkel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy S, Hong Y, Houston-Miller N, Lauer RM, Ockene IS, Sacco R, Sallis Jr. JF, Smith Jr. SC, Stone NJ, Taubert KA. AHA guidelines for primary prevention of heart disease and stroke: 2002 update. *Circulation* 2002;106:388-91.
- 242.\* Pearson TA. Post-MI risk factor management: The scope of the problem. *Cardiology Review* 2002;19(8 Suppl):3-5.
- 243.\* Pearson TA. A call to action: Recommendations for optimal risk management after MI. *Cardiology Review* 2002;19(8 Suppl):31-3.
244. Walsh MN, Simpson RJ, Wan GJ, Weiss TW, Alexander CM, Markson LE, Berger ML, Pearson TA. Do disease management programs for patients with coronary heart disease make a difference? Experience of nine practices. *Am J Manag Care* 2002;8(11):937-46.
- 245.\* Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith Jr. SC, Taubert K, Tracy RP, Vinicor F. Markers of inflammation and cardiovascular disease. *Circulation* 2003;107:499-511.
- 246.\* Pearson TA, Bazzarre TL, Daniels SR, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Hong Y, Mensah GA, Sallis Jr. JF, Smith Jr. S, Stone NJ, Taubert KA. AHA guide for improving cardiovascular health at the community level. A statement for public health practitioners, healthcare providers, and health policy makers from the AHA Expert Panel on Population and Prevention Science. *Circulation* 2003;107:645-51.
247. Olson CM, Strawderman MS, Hinton PS, Pearson TA. Gestational weight gain and postpartum behaviors associated with weight retention and major weight gain following pregnancy. *International Journal of Obesity* 2003;27:117-27.
- 248.\* Pearson TA. Education and income: double-edged swords in the epidemiologic transition of cardiovascular disease. *Ethnicity & Disease* 2003;13:S2-158—S2-163.

249. Berry DA, Berry SM, McKellar J, Pearson TA. Comparison of the dose-response relationship of two lipid-lowering agents: a Bayesian meta-analysis. *Am Heart J* 2003;145:1036-45.
250. Schwartz RG, Pearson TA, Williford DJ, Mackin ML, Awasthi A, Shah A, Kalaria VG. Prospective serial evaluation of myocardial perfusion and lipids during the first six months of Pravastatin therapy: coronary artery disease regression SPECT monitoring trial. *J Am Coll Cardiol* 2003;42:600-10.
251. Pearson TA, Barker WH, Fisher SG, Trafton SH. Integration of cases in population-oriented prevention into a problem-based medical curriculum. *Am J Prev Med* 2003;24(4S):102-107.
- 252.\* Pearson, TA. Drug-induced Metabolic Syndrome: A New Epidemic. *Preventive Medicine in Managed Care Supplement* December 2003, Vol 3, No. 2 Sup.
253. Pearson, TA. Coronary Heart Disease: Mortality, Incidence, and Opening Doors to Therapy. *Physician's Weekly*. Oct. 6, 2003, Vol. XX, No. 37.
254. Pearson, TA. Commentary: Cholesterol Trends Underscore Stalled Progress. *Lipid Management – Report from the National Lipid Education Council*. Vol. 8, No. 4 Winter 2003/2004.
255. Pelkman CL, Fishell VK, Maddox DH, Pearson TA, Mauger DT, Kris-Etherton PM. Effects of a moderate-fat (high-MUFA) and low fat, weight-loss diet on the serum lipid profile in overweight and obese men and women. *Am J Clin Nutr* 2004; 79(2):204-212.
256. Rothenberg BM, Mukamel D, McDermott M, Pearson T, Zwanziger J. Disparities in access to high quality cardiac surgeons: race, income, and hospital effects. *Ann Thorac Surg* 2004; 78: 18-25.
- 257.\* Lewis, V, Pearson, TA. Prevention of Heart Disease-Beyond Hormone Replacement Therapy. *American Society for Reproductive Medicine. Menopausal Medicine*. Volume 11, Number 2, Summer 2003.
- 258.\* Pearson, TA. Positioning Technology to Serve Global Health: The 5<sup>th</sup> International Heart Health Conference. *Eur. J. Card. Prevent. & Rehab* 2004, Vol 11 No 4, 265-266.
- 259.\* Erhardt, LR, Pearson, TA, Bruckert, E, Leiter, LA, Conroy, RM, Hobb, F.D. R, Smaha, LA, Ducimetière, Assmann, G, Fruchart, JC, Komadja, M, Olsson, AG, Wood, DA. Guidelines and their Implementation: A Discussion Document Focused on the Best Approaches to Drive Improvement. *Vascular Disease Prevention*, 2004, 1, 167-174.
260. Bazarian, JJ, Fisher, SG, Flesher, W, Lillis, R, Knox, KL, Pearson, TA. Lateral automobile Impacts and the Risk of Traumatic Brain Injury. *Ann Emerg Med*, 2004, 44: 142-152.
261. Ingster, LM, Pearson, TA. Aspirin use among heart attack survivors aged 45 and over, USA., 1971-2000. 2004. Submitted.

262. Nafziger, AN, Stenlund, H, Wall, S, Lundberg, V, Weinehall, L, Pearson, TA. Shifting Body Mass Distributions in Predominantly Rural Communities: A Comparison of Northern Sweden and Upstate New York, 2006. Submitted.
- 263.\* Pearson, TA. Introduction. Expanding Primary Prevention Efforts: Allowing Consumers Access to Over-the-Counter Statins. *Am J Cardiol* 2004; 94(9A):1F-3F.
- 264.\* Pearson, TA. The Epidemiologic Basis for Population-wide Cholesterol Reduction in the Primary Prevention of Coronary Artery Disease. *Am J Cardiol* 2004; 94(9A):4F-8F.
- 265.\* Smith, SC Jr., Jackson, R, Pearson, TA, Fuster, V, et al. Principles for National and Regional Guidelines on Cardiovascular Disease Prevention. *Circulation* 2004; 109: 3112-3121.
266. Pearson, TA, Denke, MA, McBride, PE, et al. A Community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP III Goals for LDL Cholesterol in Hypercholesterolemic Patients: The Ezetimibe Added to Statin Effectiveness (EASE) Study. *Mayo Clinic Proceedings* 2005; 80: 587-595.
- 267.\* Davies, MG, Waldman, DL, Pearson, TA. Comprehensive Endovascular Therapy for Femoropopliteal Arterial Atherosclerotic Occlusive Disease. *J Am Coll Surg* 2005; Vol. 201, No. 2, 275-296.
268. Mukamel, DB, Glance, LG, Weimer, DL, Pearson TA, et al. Surgeons Learning New Techniques and Patients' Race: Evidence from CABG surgery in New York State. *Journal of Health Services Research & Policy*. Scheduled for publication January 2007.
269. Rubin J, Kim HJ, Pearson TA, et al. Apo(a) size and PNR explain African American-Caucasian differences in allele-specific apo(a) levels for small but not large apo(a). *J of Lipid Res.* 2006 (May); 47 (5): 982-9.
270. Davidson, MH, Maki, KC, Pearson, TA, et al. Undertreatment among high-risk dyslipidemic patients: results of a national survey of goal achievement for National Cholesterol Education program Adult Treatment Panel III guidelines. *International Journal of Clinical Practice* 2005, Vol. 59, 3.
271. Pearson, TA, Denke, M, McBride, P, et al. Effectiveness of the Addition of Ezetimibe to Ongoing Statin Therapy in Modifying Lipid Profiles and Attaining Low-Density Lipoprotein Cholesterol Goals in Older and Elderly Patients: Subanalyses of Data from a Randomized, Double-Blind, Placebo-Controlled Trial. *The American Journal of Geriatric Pharmacotherapy* 2005, Vol 3, 4. [PMID: 16503317](#)
- 272.\* Smith, Jr., SC, Allen, J, Blair, SN, Bonow, RO, Brass, LM, Fonarow, GC, Grundy, SM, Hiratzka, L, Jones, D, Krumholz, HM, Mosca, L, Pasternak, RC, Pearson, T, et al. AHA/ACC guidelines for secondary prevention for patients with Coronary and Other Atherosclerotic Vascular Disease: 2006 Update. *Circulation* 2006 (May); 113: 2363-2372.
273. Nag SS, Pearson TA, Ma L, et al. Estimating Cholesterol Treatment Rates Among Individuals with Multiple Risk Factors and Without Coronary Heart Disease. *The American Journal of Cardiology*, Vol. 95, Issue 7, April 2005, 862-864.

- 274.\* Levy DR, Pearson TA. Combination niacin and statin therapy in primary and secondary prevention of cardiovascular disease. *Clinical Cardiology* 2005 (July);28(7): 317-20.
275. Levy, DR, Pearson, TA. Commentary: Aronow's "Should the NCEP III Guidelines be Changed in Elderly and Younger Persons at High Risk for Cardiovascular Events?" What Do We Do for the Very Old?" *Journal of Gerontology: Biological Sciences* 2005, Vol. 60A, No. 5, 593-602.
276. Davidson, MH, Maki, KC, Pearson, TA, et al. Results of the National Cholesterol Education Program (NCEP) Evaluation Project Utilizing Novel E-Technology (NEPTUNE II) Survey and Implications for Treatment Under Recent NCEP Writing Group Recommendations. *Am J Cardiology* 2005 (Aug); 96, 556-563.
277. Bhatt DL, Fox, KA, Hacke W, et al. Clopidogrel and Aspirin versus Aspirin Alone or the Prevention of Atherothrombotic Events. *N Engl J Med.*2006 (April); 354, 1706-1717.
278. Pearson TA, Ridker P, Ballantyne CM, McCrarity C, et al. Effects of Ezetimibe/Simvastatin Compared to Simvastatin and Atorvastatin Monotherapy in Reducing C-Reactive Protein and Low Density Lipoprotein-Cholesterol. *Am J Cardiol.* 2007 June 15;99 (12): 1706-1713.
279. Barter PJ, Ballantyne CM, Carmena R, Pearson TA, et al. Apo B versus cholesterol in Estimating Cardiovascular Risk and in Guiding Therapy: Report of the Thirty-Person/Ten Country Panel. *J Intern Med*, 2006 March; 259(3): 247-58.
280. Pearson TA, Denke MA, McBride PE, et al. Effectiveness of Ezetimibe Added to Ongoing Statin Therapy in Modifying Lipid profiles and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients of Different Races and Ethnicities : A Substudy of the Ezetimibe Add-On to Statin for Effectiveness Trial. *Mayo Clin Proc* 2006 (September);81(9): 1177-85.
281. Nafziger AN, Stenlund H, Wall S, Jenkins PL, Lundberg V, Pearson TA, Weinehall L. High Obesity Incidence in Northern Sweden: How will Sweden look by 2009? *European Journal of Epidemiology* (2006) 21:377-382
282. Anuurad E, Rubin J, Lu G, Pearson TA, et al. Protective Effect of Apolipoprotein E2 on Coronary Artery Disease in African Americans is Mediated Through Lipoprotein Cholesterol. *J Lipid Res.* 2006 Nov; 47(11): 2475-81.
- 283.\* Pearson TA, Kopin LA. Gender Disparities in the Diagnosis, Treatment, and Prevention of Coronary Heart Disease – Are Men and Women Treated Equally? *CMD Management Vol II, No 2*
284. Mukamel DB, Glance LG, Weimer DL, Pearson TA, et al. Racial variations in the choice of on-pump versus off-pump CABG surgery. *Journal for Health Services Research and Policy.* Vol 12, No 1 (31-5), Jan 2007.
285. Stenlund H, Jenkins P, Norberg M, Pearson TA, et al. Development of a New Model for Myocardial Infarction Risk: The Vasterbotten Intervention Program Equation for Risk (VIPER). Submitted.
- 286.\* Pearson, TA. The Prevention of Cardiovascular Disease: Have We Really Made Progress? *Health Affairs* (2007) 26 (1):49-60.

- 287.\* Block, RC, Pearson, TA. The Cardiovascular Implications of Omega-3 Fatty Acids. *Folia Cardiologica* (2006) Vol 13, No 7: 557-569.
288. Wang, TH, Bhatt, DL, , Fox , KA, et al. An Analysis of Mortality Rates with Dual Antiplatelet Therapy in the Primary Prevention Population of the CHARISMA Trial. *European Heart Journal* 2007 28 (18): 2200-2207.
- 289.\* Kopin, LA, Pearson TA. In the Clinic. Dislipidemia. *Ann Intern Med* 2007; 147: ITC9-1-ITC9-16.
- 290.\* Block, RC, Pearson, TA. Organizing Services for Cardiovascular Prevention. *Current Treatment Options in Cardiovascular Med.* 2007 Aug; 9 (4): 278-86.
291. Bhatt, DL, Flather, MD, Hacke, W, et al. Patients with Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial. *J AM Coll Cardiol.* 2007 May 15; 49(19): 1982-8.
292. Nafziger, AN, Lindvall, K, Pearson, TA, et al. Who is Maintaining Weight in a Middle-Aged Population in Sweden? A Longitudinal Analysis over 10 Years. *BMC Public Health* 2007, 7:108. [PMCID: PMC1904206](#)
293. Anuurad, E, Lu, G, Rubin J, Pearson, TA. ApoE Genotype Affects Allele-specific apo[a] Levels for Large Apo[a] sizes in African Americans: The Harlem Bassett Study. *J Lipid Res*, 2007, Volume 48: 693-698.
294. Anuurad E, Chiem A, Pearson TA, Berglund L. Metabolic Syndrome Components in African-Americans and European-American Patients and its Relation to Coronary Artery Disease. *Am J Cardiol.* 2007 Sep 1;100(5):830-4.
295. Berglund L, Lefevre M, Pearson TA, et al. Comparison of Monounsaturated Fat with Carbohydrates as a Replacement for Saturated Fat in Subjects with a High Metabolic Risk Profile: Studies in the Fasting and Postprandial States. *Am J Clin Nutr.* 2007, Dec; 86(6): 1611-20.
296. Anuurad E, Rubin J, Chiem A, Tracy RP, Pearson TA, Berglund L. High Levels of Inflammatory Biomarkers are Associated with Increased Allele-specific apo(a) levels in African Americans. *J Clin Endocrinol Metab* 2008 Apr; 93(4): 1482-8. [PMCID: PMC2291489](#)
297. Lu G, Chiem A, Anuurad E, Havel PJ, Pearson TA. Adiponectin Levels are Associated with Coronary Artery Disease Across Caucasian and African-American Ethnicity. *Transl Res* 2007 June; 149(6): 317-23.
298. Lande MB, Pearson TA, Vermillion RP, Auinger P, Fernandez ID. Elevated Blood Pressure, Race/Ethnicity, and C-Reactive Protein in Children and Adolescents. *Pediatrics* 2008;122:1252-1257.
299. Vaidya D, Yanek, LR, Moy TF, Pearson, et al. Incidence of Coronary Artery Disease in Siblings of Patients with Premature Coronary Artery Disease: 10 Years of Follow-up. *Am J Cardiol* 2007. Nov 1;100 (9): 1410-5. [PMCID: PMC2128738](#)

300. Rubin J, Kim HJ, Pearson TA, et al. The Apolipoprotein(a) Gene: Linkage Disequilibria at Three Loci Differs in African Americans and Caucasians. *Atherosclerosis*. 2008 Nov; 201(1):138-47. [PMCID: PMC2784197](#)
- 301.\* Pearson, TA, Manolio, TA. How to Read a Genome-wide Association Study. *JAMA*. March 2008, Vol. 299, No. 11; 1335-1344.
302. McIntosh S, Block RC, Kapsak G, & Pearson TA. Training Medical Students in Community Health: A Novel Required Fourth-Year Clerkship at the University of Rochester. *Academic Medicine*, 2008; 83(4):357-364. [PMCID: PMC3332332](#)
303. Clark LT, Maki KC, Galant R, Maron DJ, Pearson TA, Davidson MH. Ethnic Differences in Achievement of Cholesterol Treatment Goals. Results from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II. *J Gen Intern Med* 2006. April; 21 (4):320-6. [PMCID 1484721](#)
- 304.\* Farris RP, Pearson T, Fogg T, Bryant L, Peters K, Keyserling T, Fitzpatrick A, Neal W. Building capacity for heart disease and stroke prevention research: the cardiovascular health intervention research and translation network. *Health Promot Pract*. 2008 Jul;9(3):220-7.
305. Dozier A, Pearson TA, Dye T, Block R. Cardiovascular Health in the Developing World: Community Perceptions from Carriacou, Grenada. *CVD Prevention and Control* (2008) 3, 123-131. [PMCID: PMC2707836](#)
306. Pearson TA, Ballantyne CM, Veltri E, et al. Pooled Analyses of Effects on C-reactive Protein and Low Density Lipoprotein-Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy. *Am J Cardiol* 2009. Feb. 1;103(3): 369-74.
- 307.\* Benjamin EJ, Bittner V, Pearson TA. A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing committee to Develop Clinical Performance Measures for Primary Prevention of Cardiovascular Disease). August 2008.
- 308.\* Pearson TA. Heightened Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis. (Guest Editor). Supplement to the *American Journal of Medicine*. Oct. 2008. Volume 121 – Number 10A – S32-4.
- 309.\* Pearson, TA. Where Do We Go From Here? *Am J Med* 2008 Oct; 121(10 Suppl 1): S32-4.
310. Anuurad E, Tracy RP, Pearson TA, et al. Synergistic Role of Inflammation and Insulin Resistance as Coronary Artery Disease Risk Factors in African Americans and Caucasians. *Atherosclerosis*. 2009. Jul; 205(1):29-5Dec. 6. [PMCID 2700183](#)
- 311.\* Pearson TA. Commentary. Translation of Evidence-Based Guidelines in Preventive Cardiology: the EUROACTION Program. *Nature Clinical Practice Cardiovascular Medicine* 2009, Vol. 6, No 1, 8-9.
- 312.\* Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC Jr, Havas S, Labarthe DR, Limacher MC, Lloyd-Jones DM, Mora S, Pearson TA, et al. AHA/ACCF [corrected] 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of

- Cardiology Foundation/American Heart Association task force on performance measures (writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. *Circulation*. 2010 Jun 15;121(23):e445-6.
313. Anuurad E, Tracy RP, Pearson TA, et al. Comparison of C-Reactive Protein and Metabolic Syndrome as Cardiovascular Risk Factors in African-Americans and European-Americans. *Am J Cardiol* 2009 Feb 15;103(4): 523-7. [PMCID 3051347](#)
314. Anuurad E, Yamasaki M, Shachter N, Pearson TA, Berglund L. ApoE and ApoC-I Polymorphisms: Association of Genotype with Cardiovascular Disease Phenotype in African Americans. *J Lipid Res*. 2009. July 2009; 5(7): 1472-8 [PMCID 2694345](#)
315. Stenlund H, Lönnberg G, Jenkins P, Norberg M, Persson M, Messner T, Boman K, Pearson T, Wall S, Nyström L, Weinehall L. Fewer Deaths from Cardiovascular Disease than Expected from the Systemic Coronary Risk Evaluation Chart in a Swedish Population. *European Journal of Cardiovascular Prevention & Rehabilitation*. June 2009. Vol. 16; 321-324
316. Effect of Irbesartan and Enalapril in Non-ST Elevation Acute Coronary Syndrome: Results of the Randomized Double-Blind ARCHIPELAGO Study. *European Heart Journal*. August 2009. Vol. 30, Issue 22, 2733-2741.
317. Adams, (M)J, Dozier A, Shore RE, Lipshultz SE, Schwartz RG, Constine LS, Pearson, TA, Stovall M, Winters P, Fisher SG. Breast Cancer Risk 55+ Years after Irradiation for an Enlarged Thymus and Its Implications for Early Childhood Medical Irradiation Today. *Cancer Epidemiol Biomarkers Prev*. January 2010; 19(1): 48-58 [PMCID 2939494](#)
- 318.\* Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff DC Jr., Havas S, Labarthe, DR, Limacher MC, Lloyd-Jones DM, Mora S, Pearson TA, et al. ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures for Primary Prevention of Cardiovascular Disease) developed in collaboration with the American Academy of Family Physicians; American Association of Cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association: endorsed by the American College of Preventive Medicine, American College of Sports Medicine, and Society for Women's Health Research. *J Am Coll Cardiol*. 2009 Sep 29;54(14):1364-405.
319. Anuurad E; Ozturk Z; Enkhmaa B; Pearson TA; Berglund L "Association of Lipoprotein-Associated Phospholipase A2 with Coronary Artery Disease in African-Americans and Caucasians." *The Journal of Clinical Endocrinology and Metabolism*. May 2010. 95(5): 2376-83. [PMCID 2869550](#)
320. Enkhmaa B, Anuurad E, Zhang W, Pearson TA, Berglund L. Association of Lp-PLA(2) Activity with Allele-Specific Lp(a) Levels in a Bi-Ethnic Population. *Atherosclerosis*. August 2010. 211(2): 526-30. [PMCID 2914160](#)

- 321.\* Pearson T, Chockalingam A, Bilchik B, et al. Global Education and Training in Heart Disease and Stroke Prevention. In preparation.
322. Enkhmaa B, Anuurad E, Zhang Z, Pearson TA, Berglund L. Usefulness of Apolipoprotein B/Apolipoprotein A-1 Ratio to Predict Coronary Artery Disease Independent of the Metabolic Syndrome in African Americans. *Am J Cardiol.* 2010 Nov 1; 106(9):1264-9. [PMCID 2975905](#)
323. Topol, EJ, Bousser M-G, Fox KAA, Pearson TA, et al. Rimonabant for Prevention of Cardiovascular Events (CRESCENDO): a Randomized, Multicentre, placebo-controlled trials. *Lancet.* Vol. 376, Issue 9740; 517-523. August 2010.
- 324.\* Friedewald VE, Ganz P, Kremer JM, Mease PJ, O'Dell JR, Pearson TA, et al. AJC Editor's Consensus: Rheumatoid arthritis and Atherosclerotic Cardiovascular Disease. *Am J Cardiol.* 2010 Aug 1; 106(3): 442-7.
- 325.\* Ton, TGN, Fogg TT, Fong CT, John C, Li, SXL, Marshall JA, Peters K, Neal W, Pearson T. Knowledge, Perception, and Behaviors of Relatives of Persons with Premature Heart Disease: A Systematic Literature Review. *Circulation* 2011, 124:958-964.
- 326.\* Barnett S, McKee, M, Smith SR, Pearson TA. Deaf Sign Language Users, Health Inequities and Public Health: Opportunity for Social Justice. *Prev Chronic Dis* 2011;8 (2). [PMCID 3073438](#)
- 327.\* Goldstein LB, Bushnell CD, Adams RJ, Appel L, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, Pearson, TA. AHA/ASA Guidelines for the Primary Prevention of Stroke. A Statement for Healthcare Professionals from the American Heart Association/American Stroke Association Council on Stroke. *Stroke* 2011. Feb. 42(2) 517-84.
328. Barnett, S, Klein JD, Pollard RQ, Samar V, Schlehofer D, Starr M, Sutter E, Yang H, Pearson TA. Community Participatory Research with Deaf Sign Language Users to Identify Health Inequities. *AJPH*, 2011 Dec; 101(12):2235-8.
329. Adams MJ, Shore RE, Dozier A, Lipshultz SE, Schwartz RG, Constine, LS, Pearson TA, Stovall M, Thevenent-Morrison K, Fisher SG. Thyroid Cancer Risk 40+ Years after Irradiation for an Enlarged Thymus: An Update of the Hempelmann Cohort. *Radiation Research*, Dec 2010; 174: 753-762. [PMCID: PMC3080025](#)
- 330.\* Geba D, Pearson TA. Identification of Persons at Risk for Diabetes Mellitus: Can Comparative Effectiveness Research Provide the Answer? *American Journal of Preventive Medicine.* 2011;40(1):101-103.
331. Elder J, Schwartz R, Fisher SG, Pearson TA, Mieszczyńska H, van Wijngaarden E. Prospective Comparison of LVEF Cut-Off Values for Prediction of Cardiac Death Among Women with Suspected Ischemia. Resubmitted.
- 332.\* Pearson TA, Fogg TT, Bennett N, Kiebertz K, Kitzman H, Moxley R, Puzas E. Building Capacity Across the Spectrum of Research Translation: Centers of Excellence Within the Rochester Clinical and Translational Science Institute. *Clin Transl Sci.* 2010 Dec; 3(6):272-4. [PMCID 3098049](#)



- 333.\* Appel LJ, Frohlich E, Hall JE, Pearson, TA, Sacco R, Seals D, Sacks F, Smith S, Vafiadis DK, Van Horn L. The Importance of Population-wide Sodium Reduction as a Means to Prevent Cardiovascular Disease and Stroke: A Call-to-Action from the American Heart Association. *Circulation*. 2011 Mar 15; 123(10): 1138-43.
- 334.\* Hazard M, Steele S, Wang D, Pearson T, Scheideler M, Dewhurst S. CTSA-IP: A Solution to Identifying and Aggregating Intellectual Property across the NIH Clinical-Translational Science Award (CTSA) Consortium of Biomedical Research Institutes. *Clin Transl Sci* 2011 Oct; 4(5): 328-331.
- 335.\* Pearson, TA. Public Policy Approaches to the Prevention of Heart Disease and Stroke. *Circulation*. 2011, 124:2560-2571.
336. Block RC, Dozier AM, Hazel-Fernandez L, Guido J, Pearson TA. An Epidemiologic Transition of Cardiovascular Risk in Carriacou and Petite Martinique, Grenada: the Grenada Heart Project, 2005-2007. *Preventing Chronic Disease*. 2012;9:E90. Epub 2012 Apr 19. [PMCID 3406739](#)
337. Anuurad E, Enkhmaa B, Ozturk Z, Zhang W, Tracy RP, Pearson TA, et al. Age as a Modulator of Inflammatory Cardiovascular Risk Factors: Studies in African Americans and Caucasians. *ArteriosclerThromb Vasc Biol*. 2011 Sept; 31(9): 2151-6. [PMCID 3158295](#)
338. McKee MM, Barnett SL, Block RC, Pearson, TA. Impact of Communication on Preventive Services Among Deaf American Sign Language Users. *Am J Prev Med* 2011;41(1):75-79. [PMCID 3117257](#)
- 339.\* Moreno M, Pearson TA. Invited Commentary. The Quality of Lifestyle and the Quality of Life. *Arch Intern Med* Vol. 171(20) 1819-20; Nov. 14, 2011. [NIHMS364176](#)
340. McKee M, Thew D, Starr M, Kushalnagar P, Reid JT, Graybill P et al. Engaging the Deaf Sign Language Community: Lessons from a Community-Based Participatory Research (CBPR) Center. *Prog Community Health Partners*. 2102;6:319-328.
341. Enkhmaa B, Anuurad E, Ozturk Z, Zhang W, Pearson, TA, Berglund L. Differential Associations of Serum Amyloid A and Pentraxin-3 With Allele-specific Lipoprotein(a) levels in African Americans and Caucasians. *Transl Res*. 2011. Aug; 158(2): 92-8. [PMCID 3137802](#)
- 342.\* Mason K, Chockalingam A, Prudhomme S, Stachenko S, Pearson TA. Policy Depot: A Tool to Build Global Capacity in Cardiovascular Health Policy. *Global Heart* , Vol. 7, No.1 2012.
343. Mascette AM, Bernard G, Goldner JA, Harrington R, Harris PA, Pearson TA, Ramsey B, Wagner TH. Report on the National Heart, Lung, and Blood Working Group on Optimization of the IRB Process: Are Central IRBs the Solution? *Acad Med*. 2012 Oct 22.
344. Shamooh H, Center D, Davis P, Pearson TA, et al. Preparedness of the CTSA's Structural and Scientific Assets to Support the Mission of the National Center for Advancing Translational Sciences (NCATS). *Clin Transl Sci*. 2012 Apr;5(2):121-9. doi: 10.1111/j.1752-8062.2012.00401.x. Epub 2012 Mar 27.

345. Skerritt MR, Block RC, Pearson TA, Young, KC. Carotid endarterectomy and carotid artery stenting utilization trends over time. *BMC Neurology* 2012, 12:17. [PMCID: 3355040](#)
346. Pearson, TA, Palaniappan LP, Artinian NT, et al. American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 Update. A Statement for Public Health Practitioners, Healthcare Providers and Health Policy Makers. *Circulation* 2013; 127: 1730-1753
347. McKee M, Smith S, Barnett S, Pearson TA. Training Deaf and Hard of Hearing Doctors: Why and How? *Academic Medicine* 2013, 88:158-161
348. Hill AM, Stewart PW, Fung MK, **Kris-Etherton** PM, Ginsberg HN, Tracy RP, Pearson TA, Lefevre M, Reed RG, Elmer PJ, Holleran S, Ershow AG; The DELTA (Dietary Effects on Lipoproteins-Thrombogenic Activity) Investigators. *Eur J Clin Invest.* 2014 Jan 2. doi: 10.1111/eci.12235.
349. Dozier AM, Martina CA, O'Dell NL, Fogg TT, Lurie SJ, Rubinstein EP, Pearson TA. Identifying Emerging Research Collaborations and Networks: Method Development. *Eval Health Prof.* 2014 Mar;37(1):19-32. Doi: 10.1177/0163278713501693.
350. Record B, Onion DK, Prior RE, Dixon DC, Record, SS, Fowler FL, Cayer, GR, Amos, CI, Pearson TA. Community-Wide Cardiovascular Disease Prevention Programs and Health Outcomes in a Rural County, 1970-2010. *JAMA.* 2015;313(2):147-155. doi:10.1001/jama.2014.16969
351. Chan WV, Pearson TA, Cushman WC, Gaziano TA, Gorman P, Handler J, Krumholz HM, Kushner R, MacKenzie TD, Sacco RL, Smith, Jr. SC, Stevens VJ, Wells BL, Bennett GC, Shero ST, Heil SKR, Castillo G, Stephens J, Jacobson Vann JC. Clinical Practice Guideline Implementation Strategies: A Summary of Systematic Reviews by the NHLBI Implementation Science Work Group. *Journal of the American College of Cardiology* Jan 2017, 23149; DOI: 10.1016/j.jacc.2016.11.004.
352. Chan WV, Pearson TA, Cushman WC, Gaziano TA, Gorman P, Handler J, Krumholz HM, Kushner R, MacKenzie TD, Sacco RL, Smith, Jr. SC, Stevens VJ, Wells BL, Bennett GC, Shero ST, Heil SKR, Castillo G, Stephens J, Jacobson Vann JC. Clinical Practice Guideline Implementation Strategies: A Summary of Systematic Reviews by the NHLBI Implementation Science Work Group. *Circulation.* 2017;135:e122–e137. DOI: 10.1161/CIR.0000000000000481
353. McKee, MM, Paasche-Orlow, M, Winters PC, Fiscella K, Zazove P, Sen A, Pearson TA. Assessing Health Literacy in Deaf American Sign Language Users. *J Health Commun.* 2015 Oct;20 Suppl 2:92-100. doi: 10.1080/10810730.2015.1066468.
354. Gurka MJ, Golden SH, Musani SK, Sims M, Vishnu A, Guo Y, Cardel M, Pearson TA, DeBoer MD. Independent Associations Between A Metabolic Syndrome Severity Score and Future Diabetes by Sex and Race: The Atherosclerosis Risk in Communities Study and Jackson Heart Study. *Diabetologia.* 2017 Jul;60(7):1261-1270. doi: 10.1007/s00125-017-4267-6. Epub 2017 Apr 4.
355. Barnett, S.L., Matthews, K.A., Sutter, E.J., DeWindt, L.A., Pransky, J.A., O'Hearn, A.M., David, T.M., Pollard, R.Q., Samar, V.J., Pearson, T.A. Collaboration With Deaf Communities to Conduct Accessible Health Surveillance. *Am J Prev Med* 2017;52(3S3):S250–S254.

356. Pearson, TA. Understanding the impact of hyperlipidemia treatment on medical expenditures for cardiovascular disease. *Medical Care* 2017; 55(1) 1-3.
357. DeBoer MD, Gurka MJ, Hill Golden S, Musani SK, Sims M, Vishnu A, Guo Y, Pearson TA. "Independent Associations between Metabolic Syndrome Severity & Future Coronary Heart Disease by Sex and Race." (Peer-reviewed Research Letter.) *J Amer Coll Card* 69:1204-1205 (2017).

WORK PUBLISHED IN OTHER FORMS (VIDEOTAPE, COMPUTER SOFTWARE, etc.):

1. Pearson TA. Secondary prevention of coronary artery disease. *CARDIOSAT* 1:12, 1985.
2. Pearson TA. The positive exercise EKG in the asymptomatic patient. *Johns Hopkins Medical Grand Rounds Volume XI, Program 5, May, 1985* (Continuing Education Programs with slides and audio cassette).
3. Pearson TA, Becker DM. A software program for cardiovascular risk assessment for physicians at national medical conventions. Presented at national medical conventions as part of Parke-Davis Exhibit.
4. Pearson TA. Cigarette addiction. *Johns Hopkins Medical Grand Rounds*. In press (Continuing Education Programs with slides and audio cassette).
5. Pearson TA. Premature coronary artery disease. *Johns Hopkins Medical Grand Rounds*. In press (Continuing Education Programs with slides and audio cassette).
6. Pearson TA, Becker DM. The Johns Hopkins Physicians' Lipid Education Program (Continuing Education Programs with text, audio cassette, computer feedback).
7. Contributor to Cardiology Section of Medical Knowledge Self-Assessment Program VIII (MKSAPVIII), American College of Physicians, 1989.
8. Becker D, Pearson T. A software program for cardiovascular risk assessment in physicians at national medical conventions. Presented at the 6<sup>th</sup> Annual Meeting of the Preventive Cardiology Academic Awardees, Bethesda, Maryland, April, 1985.
9. Pearson TA. The cholesterol crusade. Screening guidelines and treatment strategies. *Audio Digest* 35 (Number 10), May 18, 1988 (Audiotape).
10. Pearson TA, Becker DM, Sigmund W, Wilder L. The Johns Hopkins Physicians' Lipid Education Program, Part II, 1988.
11. Pearson TA, Boekeloo B. A preventive cardiology program for the premenopausal woman. Berlex, Inc., 1988 (monograph, tape, videotape).
12. Pearson TA. Epidemiology and prevention of atherosclerotic diseases. *Cardiovascular Medicine, American College of Physicians, MKSAP IX*, 1992.
13. Hernandez T, Santanello N, Crystal J, Heine D, Heine A, Pearson TA. CHAMP (Cholesterol Assessment and Management Program): An interactive videodisc program to teach

Implementation of the National Cholesterol Education Program (NCEP). National Conference On Cholesterol and High Blood Pressure Control, Washington, DC, April, 1991.

14. Preventive Cardiology Center Management Software. Copyright, University of Rochester, 1998.
15. Pearson TA. Cardiovascular medicine in the 21<sup>st</sup> century: Emerging strategies for the prevention of coronary heart disease and stroke, 1998. (Cassette and companion guide).
16. Brown KL, Pearson TA. April 1999 Commentary: Heart disease in the developing world. ProCOR website: [www.healthnet.org](http://www.healthnet.org). May, 1999.
17. Pearson TA. Glucose intolerance in diabetics with CAD. Published on the American College of Cardiology website entitled, "Implementing Coronary Risk Factor Modification." June, 1999.
18. Pearson TA. The high-risk patient without CHD. Professional Postgraduate Services, Physicians World Communications Group. Audiocassette #7342. June, 1999.
19. Pearson TA, Kopin L. Management of lipid disorders. American College of Physicians (web-based). PIER Program, 2000.
20. Pearson TA. Dyslipidemia in primary care. National Center for Quality Assurance, 2001.
21. Hunninghake DB, Pearson TA. Treating dyslipidemia: Implementation of new diagnostic and management guidelines. Donnemiller Memorial Educational Foundation, 2001.
22. Pearson TA. Questions and answers for the health care professional on the new NCEP ATP III guidelines and management of dyslipidemia in primary care. National Committee for Quality Assurance, December and January, 2001 –2002.
23. Sassetti M, Tranmer P, Edwards Jr. WL, McBride P, Pearson TA, Stone NJ. Treatment of Dyslipidemia Based on Therapeutic Targets: Recommendation for Primary Care Clinicians. Consensus from an Expert Panel. Illinois Academy of Family Physicians, Vol. 3(5): Nov., 2002.
24. Fonarow GC, Pearson TA, Sacks FM. Optimal Risk Management with Proven Therapies in Post-MI Patients at Discharge. Preventive Cardiology Clinic, a supplement to Pharmacy Times, Vol. 20, No. 1(suppl), January 2003.
25. Brown W, Mackey R, Orringer C, Pearson. Journal of Clinical Lipidology Roundtable Discussion: Gender Differences in Reduction of CVD in Response to Lipid Lowering. In Press.

#### BOOKS AND MONOGRAPHS:

1. Pearson TA, Criqui M, Luepker R, Oberman A (eds.): Primer in Preventive Cardiology. American Heart Association, 1994.
2. Pearson TA (ed.): Metabolic consequences of stearic acid relative to other long-chain fatty acids. Monograph published as supplement to American Journal of Clinical Nutrition, 1994.
3. Fuster V, Pearson TA (eds.): 27<sup>th</sup> Bethesda Conference: Mortality and intensity of risk factor

management with the hazard for coronary disease events. *J Am Coll Cardiol* 1996;27:957-1047.

4. Konstam MA, Pearson TA, Roberts WC, Smith SL (eds.): Current focus in treating and managing coronary artery disease and heart failure. *Am J Cardiol* 1997;1H-90H.
5. Stone EJ, Pearson TA (eds.): Community trials for cardiopulmonary health. Directions for public health practice, policy and research. *Ann Epidemiol* 1997;7:S1-S121.
6. Pearson TA (ed.): Obesity: A cardiovascular risk factor. Symposium proceedings for physicians. *Cardiology in Review*.
7. Pearson TA, Boden W (eds.): The imperative to raise low levels of high-density lipoprotein in cholesterol – A better clinical strategy in the prevention and treatment of coronary artery disease. *Am J Cardiol* 2000;86:1-65.
8. Pramparo P, dos Santos RD, Palmieri MG, Granero R, Hassell TA, Luna M, Champagne BM, Morillo CA, Pearson TA, et al. Guidelines for primary prevention of cardiovascular and cerebrovascular disease for Latin-America and the Caribbean: 2003 update. InterAmerican Heart Foundation, 2003.
9. Libby, P, Ridker, PM, Pearson, TA, Schwer, WA. The Role of Inflammatory Markers in CVD: Detection and Treatment. *Apollo*, October 2003.
10. Pearson, TA (Ed). Expanding Primary Prevention Efforts: Allowing Consumers Access to Over-The-Counter Statins. *Am J Cardiol* 2004, 94(9A):1F-3F.
12. Wilson, E, Farquhar, JW, O'Connor, B, Harriman, ME, MacLean, D, Pearson, TA (Eds). International Action on Cardiovascular Disease: A Platform for Success. A Synthesis of the International Heart Health Declarations, 2004.
13. MacLean, DR, Cianflone D, Pearson, TA, Stachenko, S, Bales, V, Harris V. The Milan Declaration: Positioning Technology to Serve Global Heart Health (2004).
14. Pearson, TA (Guest Editor). Heightened Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis. *Am J Med Supplement* 2008; Volume 121-Number 10A.
15. Report of the U.S. Dietary Guidelines Advisory Committee on the Dietary Guidelines for Americans, 2010. U.S. Department of Agriculture, Department of Health and Human Services, May 2010.

#### BOOK CHAPTERS:

1. Pearson TA. Asymptomatic coronary artery disease. In: *Current Therapy in Cardiovascular Disease*. Toronto: B.C. Decker, Inc., 1987:3-6.
2. Pearson TA. Coronary arteriography in women: advantages in the study of the etiology and natural history of coronary artery disease. In: *Coronary Heart Disease in Women: Proceedings of a Workshop*. New York, NY: Le Jacq Publishing, Inc., 1987, in press.
3. Pearson TA. Health maintenance and disease prevention. In: *Principles and Practice of Internal*

Medicine, 1988:24-33.

4. Herrington DM, Walford GD, Pearson TA. Issues of validation in quantitative coronary angiography. In: Reiber JHC, Serruys PW, editors. *New Developments in Quantitative Coronary Arteriography*. Dordrecht/Boston/London: Kluwer Academic Publishers, 1988.
5. Pearson TA. Smoking Cessation: the clinical evaluation and management of the cigarette smoker. In: Kelly W, editor. *Textbook of Internal Medicine*. New York, NY: J.B. Lippincott, 1989:2093-2097.
6. Pearson TA. Smoking cessation: the clinical evaluation and management of the cigarette smoker. In: Kelly W, editor. *Textbook of Internal Medicine*. New York, NY: J.B. Lippincott, 1992:1870-1874.
7. Pearson TA. Coronary intervention trials: unsolved questions. In: *Clinics in Applied Nutrition*. Andover Med. Publishers, 1992:9-17.
8. Pearson TA, Jamison DT, Trejo-Gutierrez J. Cardiovascular disease. In: *Disease Control Priorities in Developing Countries*. New York, NY: The World Bank, Oxford University Press, 1993:577-599.
9. Michaud C, Trejo-Gutierrez J, Cruz C, Pearson TA. Rheumatic fever and rheumatic heart disease. In: *Disease Control Priorities in Developing Countries*. Washington, DC: The World Bank, 1993.

BOOK CHAPTERS: (cont'd)

10. Pearson TA, Marx HJ. Reduction of risk in the patient with cardiovascular disease. In: *A Primer of Preventive Cardiology*. The American Heart Association, 1994:235-247.
11. Pearson TA, Winston M. Preventive cardiology in the 21<sup>st</sup> century. In: *A Primer of Preventive Cardiology*. American Heart Association, 1994:293-294.
12. Pearson TA. Population strategy. In: Rifkind B, editor. *Lowering Cholesterol in High-Risk Individuals and Populations*. New York, NY: Marcel Dekker, 1995:149-166.
13. Tacci J, Pearson TA, et al. Cardiovascular disease prevention panel final report. In: Novick L, editor. *Practice Guidelines for Public Health: Assessment of Scientific Evidence, Feasibility and Benefits*. Albany, NY: Council on Linkages Between Academia and Public Health Practice, 1995:38-46.
14. Pearson TA. Socioeconomic status and cardiovascular disease in rural populations. In: Stamler J, Hazuela H, editors. *Report on the Conference on Socioeconomic Status and Cardiovascular Health and Disease*. Washington, DC: National Heart, Lung, and Blood Institute, 1995:101-108.
15. Pearson TA. The human biology of reduction in dietary lipids as a strategy to prevent cardiovascular disease. In: *Beyond Nutritional Recommendations: Implementing Science for Healthier Populations*. Ithaca, NY: Division of Nutritional Sciences, Cornell University, 1996:69-86.

16. Bowlin SJ, Medalie J, Pearson TA. Cholesterol and vascular disease in the elderly. In: Vellas B, Albarede JL, Garry PJ, editors. Facts, Research and Intervention in Geriatrics Serie. Supplement: Vascular Diseases. Vascular Diseases in the Elderly. Paris: Serdi Publisher, 1997:25-47.
17. Myerson M, Pearson TA. Cholesterol lowering drugs. In: Cardiology Clinics: Annual of Drug Therapy. Philadelphia, PA: WB Saunders, 1997:159-180.
18. Pearson TA, Patel RV. Diet modification and food policy strategies: what works? In: Bobadella JL, Costello CA, Mitchell F, editors. Premature Death in the New Independent States. National Academic Press, 1997:355-374.
19. Pearson TA. Preventive cardiology in minority populations. In: Robinson KC, editor. Preventive Cardiology. Armonk, NY: Futura Publishing, 1998:277-301.
20. Pearson TA. An integrated approach to risk factor modification. In: Topol EJ, Thompson P, editors. Textbook of Cardiovascular Medicine. Philadelphia, PA: Lippincott-Raven Publishers, 1998:297-311.
21. Maron DJ, Ridker PM, Pearson TA. Risk factors and the prevention of coronary heart disease. In: Alexander RW, Schlant RC, Fuster V, editors. Hurst's The Heart, Ninth Edition. New York, NY: McGraw-Hill, 1998:1175-1195.
22. Pearson TA. The current burden of cardiovascular disease in developing countries. In: Ryan T, Reddy S, editors. Research, Development and Institutional Strengthening for Control of Cardiovascular Disease in Developing Countries. Washington, DC: National Academy of Sciences Press, 1998.
23. Fuster V, Pearson TA. Matching the intensity of risk factor modification with the hazard for coronary disease events. In: Wenger NK, Smith LK, Froelicher ES, Cosmoss PM, editors. Cardiac Rehabilitation: A Guide to Practice in the 21<sup>st</sup> Century. New York, NY: Marcel Dekker, 1999.
24. Pearson TA. Public health approaches and clinical strategies in primary prevention. In: Wong N, editor. Preventive Cardiology. New York, NY: McGraw-Hill, 2000:539-556.
25. Pearson TA, Kopin LA. Compliance of providers to guidelines. In: Burke LE, Ockene IS, editors. Compliance in Healthcare and Research. Armonk, NY: Futura Publishing, 2001.
26. Rasalingam R, Pearson TA. An integrated approach to risk factor modification. In: Topol EJ, Thompson P, editors. Textbook of Cardiovascular Medicine. Philadelphia, PA: Lippincott-Raven Publishers, 2001.
27. Pearson TA, Maron DJ, Ridker PM, Grundy SM. Dyslipidemia and risk factors in the prevention of coronary heart disease. In: Hurst's The Heart, Tenth Edition. New York, NY: McGraw-Hill, 2001.
28. Levy D, Pearson TA. Management of lipid disorders & other risk factors in patients with peripheral vascular disease. In: Textbook of Peripheral Vascular Interventions. London: Martin Dunitz Ltd, 2002.

29. Pearson, TA, Wilson, M. "Primary Prevention" In: Preventive Cardiology. McGraw Hill, Ed. 2003: 493-514.
30. Block, R, Pearson, TA "An integrated approach to risk-factor modification" In: Topol EJ, Califf RM, editors. Textbook of Cardiovascular Medicine. Philadelphia, PA: Lippincott, Williams & Wilkins, 2007:175-183.
31. Pearson, TA. "Cardiovascular Disease" in DeBuono B (Ed). Milestones in Public Health. Pfizer, Inc., 2006.
32. Kris-Etherton, PM, Pearson, TA "Moderate-risk patient with hypercholesterolemia: a pharmacy (P) model for decreasing LDL-cholesterol to reduce coronary heart disease risk" In: Betteridge, DJ. Case Studies. London, England: Informa Healthcare, 2007: 1-5.
33. Pearson, T.A., Kopin, LA. "Multifactorial Risk Factor Intervention". In: Durstine, J.L., Moore, G.E., et al. (eds). Pollock's Textbook of Cardiovascular Disease and Rehabilitation, Champaign, IL: Human Kinetics Publishing, 2008: 29-40.
34. Pearson, TA. "Clinical Trial Evidence for Treatment of Dyslipidemia in the Prevention of Cardiovascular Disease." In: Kwiterovich, PO: The Johns Hopkins Textbook of Dyslipidemia. Philadelphia, PA: Lippincott, Williams & Wilkins, 2010: Chapter 5, 58-66.
35. Pearson, TA, Kapoor, RW, Holloway, R. "Developing a Translational Research Workforce in the U.S." In the monograph series: Translational Medicine: What, Why and How –An International Perspective. Basel: S Karger, 2013: 36-46.



LETTERS TO THE EDITOR:

1. LaCroix AZ, Mead LA, Liang K-Y, Thomas CB, Pearson TA. *N Engl J Med* 1987;316:947.
2. Pearson TA. Decaffeinated coffee and serum LDL cholesterol concentrations. *Am J Clin Nutr* 1992;56:604.
3. Lewis C, Elmer P, Caggiula AW, Pearson TA, et al. Blood cholesterol measurements in young adults. *JAMA* 1993;270:936-7.
4. Pearson TA, Philbin E, Weil H. *Am J Med* 1994;97:404-6.
5. Pearson TA, Kris-Etherton P. *Am J Clin Nutr* 1996;63:400-402.
6. Pearson TA, Grundy S. *Ann Intern Med* 1996;125:1008.
7. Crouse JR, Howard G, Toole JF, Pearson TA. *JAMA* 1996;276:528-9.
8. Mosca L, Grundy SM, Judelson D, King D, Limacher M, Oparil S, Pasternak R, Pearson TA, Redberg RF, Smith SC, Winston M, Zinberg S. *Circulation* 1999, in press.
9. Ossip-Klein DJ, Pearson TA, McIntosh S, Orleans CT. Smoking is a geriatric health issue. *Nicotine and Tobacco Research* 1999;1:299-300.
10. Chirieac D, Pearson TA. *N Engl J Med* 2002;346:1094.

REVIEWS:

1. Pearson TA. *Cardiovascular Disease: Risk Factors and Intervention*. Edited by N. Poulter, P. Sever, S. Thom. Oxford: Radcliffe Medical Press, 1993, ISBN 1-870905-54-7, 351 pages, *Am J Epidemiol* 1994;140:66-8.
2. Pearson TA. *Coronary Heart Disease Epidemiology: From Aetiology to Public Health*. Edited by M. Marmot, P. Elliott. Oxford: Oxford University Press, 1992, ISBN 0-19-26233124-6, 547 pages, *Am J Epidemiol* 1994;140:66-8.
3. Pearson TA. Birth weight and adult hypertension and obesity in women. (Review). *Coronary Artery Disease Index and Reviews* 1996;11:5.
4. Pearson TA. Lowering risk without lowering cholesterol: implications for national cholesterol policy. (Review). *Coronary Artery Disease Index and Reviews* 1996;11:8.
5. Pearson TA. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. (Review). *Coronary Artery Index and Reviews* 1996;11:9.
6. Pearson TA. *Lipids and Vascular Disease: Current Issues*. Edited by D. J. Betteridge. London: Martin Dunitz, 2000, ISBN 1-85317-627-3, 262 pages, *N Engl J Med* 2001;344(7):534-5.